

the surgical pathology files of the Department of Pathology, Tohoku University Hospital, Sendai, Japan. Breast tissue specimens were obtained from Japanese female patients who underwent a mastectomy during 1988–1999 in the Department of Surgery, Tohoku University Hospital, Sendai city, Japan. The mean age was 52.9 years (range, 22–81 years). None of the patients examined in the present study received chemotherapy, administration of trastuzumab or irradiation prior to surgery. The mean follow-up time was 81 months (range, 1–151 months). All of the specimens had been fixed in 10% formalin at room temperature and embedded in paraffin wax. Research protocols for this study were approved by the Ethics Committee at Tohoku University School of Medicine (approval number 2005-178).

**Antibodies.** Mouse monoclonal antibody for human Runx2 was purchased from Abnova Corporation (Taipei, Taiwan). The characterization of this antibody has been previously reported using both immunoblotting and immunohistochemistry.<sup>(40)</sup> Monoclonal antibodies for estrogen receptor  $\alpha$  (ER1D5), progesterone receptor (PR; MAB429) and Ki-67 (MIB1) were purchased from Immunotech (Marseille, France), Chemicon (Temecula, CA, USA) and DAKO (Carpinteria, CA, USA), respectively. We used a standardized immunohistochemistry kit (HercepTest for Immunoenzymatic Staining; DAKO).

**Immunohistochemistry.** A Histofine kit (Nichirei, Tokyo, Japan), which uses the streptavidin–biotin amplification method, was used in this study. Antigen retrieval was carried out by heating the slides in an autoclave at 120°C for 5 min in citric acid buffer (2 mM citric acid and 9 mM trisodium citrate dehydrate, pH 6.0) for Runx2, ER, PR, HER2 and Ki-67 immunostaining. The dilutions of the primary antibodies used in this study are as follows: Runx2, 1/1000; ER, 1/50; PR, 1/30; HER2, 1/200; and Ki-67, 1/50. The antigen–antibody complex was visualized with 3,3'-diaminobenzidine (DAB) solution (1 mM DAB, 50 mM Tris-HCl buffer [pH 7.6] and 0.006% H<sub>2</sub>O<sub>2</sub>), and counterstained with haematoxylin. As a negative control, normal mouse, rabbit or goat IgG was used instead of the primary antibodies, and no immunoreactivity was detected in these sections (data not shown).

**Statistical analysis.** Immunoreactivity of Runx2 was detected in the nuclei and the labeling index (LI) was subsequently obtained. Briefly, Runx2 immunoreactivity was evaluated in the nuclei of more than 1000 carcinoma cells for each case, and the percentage of immunoreactivity (i.e. the LI) was subsequently determined. In breast carcinoma cells, Runx2, ER, PR and Ki-67 immunoreactivity was detected in the nucleus, and the immunoreactivity was evaluated as a LI in the same way as described above. Cases with ER, PR or Ki-67 of more than 10% were considered positive in this

study, according to a report on ER.<sup>(41)</sup> HER2 immunoreactivity was evaluated according to a grading system proposed in HercepTest (DAKO), and moderately or strongly circumscribed membrane staining of HER2 in more than 10% of carcinoma cells was considered positive.<sup>(42)</sup> An association between Runx2 immunoreactivity and clinicopathological factors of breast carcinoma patients was statistically evaluated using a correlation coefficient (*r*) and regression equation, Student's *t*-test, or a one-way ANOVA and Bonferroni test. Overall and disease-free survival curves were generated according to the Kaplan–Meier method, and the statistical significance was calculated using the log-rank test evaluating 64 cases with the Runx2 LI  $\geq 37\%$  (median value) as Runx2 positive and 56 cases with the Runx2 LI  $< 37\%$  as Runx2 negative in a group of non-distal metastatic breast cancer. Both univariate and multivariate analyses were evaluated by a proportional hazard model (COX) using PROC PHREG in SAS software (SAS Institute Inc., Cary, NC, USA).

## Results

**Immunohistochemistry of Runx2.** Runx2 immunoreactivity was detected in the nuclei of breast carcinoma cells (Fig. 1a,b), and the mean value of the Runx2 LI in 137 breast carcinoma tissues examined was 43.1% (range, 0–99%) in total. Runx2 immunoreactivity was also detected in non-pathological myoepithelial and ductal cells (Fig. 1c). Ninety-five cases are ER positive (LI  $\geq 10\%$ ) and 42 cases are ER negative (LI  $< 10\%$ ). Seventy-eight cases are PR positive (LI  $\geq 10\%$ ) and 59 are PR negative (LI  $< 10\%$ ). The mean value  $\pm$  SD of the Ki-67 LI in 137 breast carcinoma tissues examined was 21.3  $\pm$  17.9% (range, 0–82%) in total.

**Correlation of the Nucleus Runx2 LI with the clinicopathological factors of the cases examined.** Table 1 summarizes the correlation of the Runx2 LI in breast carcinoma cells with the clinicopathological parameters in the breast carcinoma cases. Significant association between the Runx2 LI and stage ( $P = 0.0004$ ), histological grade ( $P = 0.046$ ) and HER2 status ( $P = 0.002$ ) of the patients was demonstrated, but there were no significant correlation between the Runx2 LI and age ( $P = 0.78$ ), menopausal status ( $P = 0.69$ ) and lymph node status ( $P = 0.66$ ) of the cases examined. The Runx2 LI tended to be correlated with ER ( $P = 0.13$ ) and PR status ( $P = 0.06$ ), but the correlation did not reach statistical significance. The Runx2 LI also correlated with both clinical stages and histological grades of the patients.

**Correlation between the Runx2 LI and clinical outcome in 120 non-distal metastatic breast carcinoma patients (stage I–III).** A significant association was detected between the Runx2 LI and recurrence ( $P = 0.01$ ) or overall survival ( $P = 0.003$ ) of the




Fig. 1. Immunohistochemistry for Runx2. Runx2 immunoreactivity was detected in the nuclei of both carcinoma and stroma cells. (a) Case I with Stage III showed a labeling index (LI) = 97.0. (b) Case II with Stage II showed a LI = 37.0. (c) Normal mammary epithelial cells also include nucleus Runx2 positive. Bar, 100  $\mu$ m.

**Table 1. Summary of an association between the nuclear Runx2 LI of carcinoma cells and the clinicopathological parameters in 137 breast cancers**

	<i>n</i>	Runx2 LI	<i>P</i> value
Age (22–81 years)	137		0.78 ( <i>r</i> = -0.024)
Menopausal status			
Premenopausal	50	43.1 ± 4.1	0.69
Postmenopausal	87	45.1 ± 2.9	
Stage			
I	34	35.3 ± 4.6	<b>0.0004</b>
II	67	42.0 ± 3.4	
III	19	47.2 ± 5.1	
IV	17	68.8 ± 5.7	
Tumor size			
<2.0 cm	18	49.8 ± 6.3	0.68
≥2.0 cm	94	46.5 ± 3.0	
Lymph node status			
Positive	17	45.5 ± 3.6	0.66
Negative	120	43.4 ± 3.2	
Distant metastasis			
Positive	60	68.8 ± 5.7	<b>&lt;0.0001</b>
Negative	77	40.9 ± 2.5	
Histological grade			
1 (well)	27	34.7 ± 5.6	<b>0.046</b>
2 (moderate)	63	43.4 ± 3.6	
3 (poor)	47	51.2 ± 3.6	
ER status			
Positive	95	41.6 ± 2.9	0.13
Negative	42	49.3 ± 3.8	
PR status			
Positive	78	40.3 ± 3.2	0.06
Negative	59	49.2 ± 3.4	
HER2 status			
Positive	30	58.3 ± 5.4	<b>0.002</b>
Negative	107	40.5 ± 2.5	
Ki-67 LI (0–82%)			<b>0.004</b> ( <i>r</i> = 0.25)

Data considered significant (*P* < 0.05) in the univariate analysis are shown in bold. Significant values were examined in the multivariate analysis in the present study. ER, estrogen receptor; LI, labeling index; PR, progesterone receptor.

patients in 120 breast carcinoma patients at stage I, II and III (Fig. 2a,b). In particular, among these 120 patients, ER negative cases (23 Runx2 positive and 20 Runx2 negative), the Runx2 LI was markedly associated with an increased risk of clinical recurrence (*P* = 0.03) (Fig. 2c) and overall survival of the patients (*P* not calculated because no patients died in the ER negative/Runx2 positive group) (Fig. 2d). However, among the ER-positive cases (41 Runx2 positive and 36 Runx2 negative), no significant association was detected between the Runx2 LI and an increased risk of recurrence (*P* = 0.55) (Fig. 2e) and overall survival (*P* = 0.39) (Fig. 2f).

In a Univariate analysis, the Runx2 LI evaluated as a continuous variable also turned out to be a significant prognostic factor (*P* = 0.049 in disease-free survival and *P* = 0.004 in overall survival), and an independent prognostic factor when it was included in a multivariate analysis instead of the dichotomized variable (*P* = 0.01 and *P* = 0.04, respectively) (Table 2). Because no cases had received administration of trastuzumab agent in this study, HER2 positive was a remarkably poor prognostic factor.<sup>(43)</sup>

## Discussion

In the present study, the Runx2 LI in breast carcinoma cells was significantly associated with stage (*P* = 0.0004) and histological


grade (*P* = 0.046) of the patients examined. These findings indicate the possible roles of Runx2 in the biological behavior of breast carcinoma patients, including those without metastasis. We also demonstrated that the prognosis or clinical outcome of cases associated with a high Runx2 LI is generally poor. In particular, in 120 cases not associated with distant metastasis, a significant positive association was detected between the Runx2 LI and both the risk of recurrence and overall survival of patients. Furthermore, this association was more pronounced in the group of 43 ER-negative cases (36%). This group of ER-negative carcinoma included HER2 positive and basal-like subgroups of breast carcinoma. These findings also suggested that Runx2 could serve as a marker of aggressive biological behavior and its inhibition might open a new strategy of therapy for these cases.

Breast cancer development consists of many sequential steps, including primary tumor growth, neovascularization around the tumor, invasion, extravasation and subsequently formation of bone metastasis.<sup>(24)</sup> Many *in vitro* studies demonstrated that Runx2 might participate in these steps in multiple fashions. Regulation or modification of VEGF secretion by Runx2 was reported in neovascularization.<sup>(44)</sup> Regulation of several MMP secretion by Runx2 was also postulated to be linked with subsequent invasion of carcinoma cells.<sup>(45,46)</sup> Runx2 was proposed to subsequently mediate PTHrP expression of metastatic breast carcinoma cells in the microenvironment of bone and might be involved in the formation of a vicious cycle.<sup>(2)</sup> All of the above might be related to an adverse clinical outcome for patients but little has actually been demonstrated in clinical cases of human breast carcinoma. In the present study, we demonstrated a significant correlation of the status of Runx2 expression in carcinoma cells with the histological grade and stage of patients. In addition, the possibility of potential involvement of Runx2 in earlier phases of breast cancer development was also raised in the present study.

In the present study, the groups of patients with elevated Runx2 expression were significantly associated with a poor prognosis in the ER-negative group of patients, while this association was not detected in the ER-positive carcinoma patients. In our cohort of ER-positive breast cancer patients, 34 of 95 cases (35.8%) received administration of tamoxifen, while in that of the ER-negative breast cancer patients, six of 42 cases (14.3%) did. Estrogenic depletion affects not only breast carcinoma cells but also the entire body of patients. It is true that SERM can prevent the systemic effects of estrogen depletion to some extent, but ovarian suppression and administration of AI result in marked side-effects, especially in the skeletal system causing development of clinically significant osteoporosis in some patients.<sup>(36–39)</sup>

Results of various *in vitro* studies have shown that suppression of estrogenic activation caused maturation of osteoclasts in a direct manner.<sup>(47)</sup> Estrogen, acting via ER, causes upregulation of Fas ligand (FasL) in osteoclast progenitors (pOC) and/or OC themselves.<sup>(47)</sup> The increased FasL levels cause apoptosis because these OC lineage cells also express Fas. Fas ligand expression is also reported to be diminished or even suppressed without estrogens in these systems, and the life span of OC was actually reported to be elongated in the absence of estrogen in a culture medium. These OC might stimulate osteoblasts to form bone via poorly defined factors but the resorptive effects of these OC are usually considered dominant.<sup>(47)</sup>

Results of several reported studies suggest that anti-estrogen therapy did amplify the maturation of OC, resulting in the development of osteoporosis. Osteoporosis is a disease of increased bone turnover, in which the bone-resorbing activity of OC outpaces the bone-forming activity of osteoblasts, resulting in the loss of predominantly trabecular bone.<sup>(47)</sup> Both of these cell types are reported to respond to estrogen, but results of previous studies suggest that the response of human bone to estrogen



**Fig. 2.** Disease-free (a) and overall (b) survival of 120 cases associated with non-distal metastatic breast carcinoma according to nucleus Runx2 immunoreactivity (Kaplan–Meier method), respectively. Disease-free (c) and overall survival (d) of 77 estrogen receptor (ER)-positive breast carcinoma cases associated with non-distal metastatic breast carcinoma according to nucleus Runx2 immunoreactivity, respectively. Disease-free (e) and overall survival (f) of 43 ER negative breast carcinoma cases associated with non-distal metastatic breast carcinoma according to nucleus Runx2 immunoreactivity, respectively.

withdrawal is at least in part mediated by a network of inflammatory and osteoclastogenic cytokines, including tumor necrosis factor  $\alpha$  (TNF $\alpha$ ) and interleukin-1 (IL-1), released by stromal/osteoblast lineage cells and T cells.<sup>(48,49)</sup>

Decreased levels of estrogens usually result in increased production of the cytokine IL-7 by osteoblasts, which stimulates proliferation of T cells and their secretion of both TNF $\alpha$  and receptor activator of NF- $\kappa$ B Ligand (RANKL).<sup>(49)</sup> Tumor necrosis factor  $\alpha$  stimulates osteoblasts to increase their synthesis of RANKL, which results in the differentiation and activation of OC. Tumor necrosis factor  $\alpha$  also acts directly on pOC, synergizing with RANKL for OC differentiation.<sup>(49)</sup> Additional pro-osteoclastogenic cytokines and growth factors are also expressed in T cells and other peripheral blood mononuclear cells.<sup>(49,50)</sup>

It is practically very difficult to confirm that bone-metastatic breast cancer cells are also associated with elevated Runx2 expression in the cases with high Runx2 expression in primary breast carcinoma cells because clinically the availability of specimens for both primary and bone metastasis are in general rare. However, metastatic breast carcinoma cells associated with high Runx2 expression may facilitate the process of osteoporosis in the bone microenvironment by RANKL secretion of osteoblasts via PTHrP secretion,<sup>(30)</sup> but further investigations are required for clarification.

HER2 status of patients turned out to be a strong independent factor because administration of Herceptin had not been used in any of the patients examined in this retrospective study. Runx2 LI in carcinoma cells was also markedly correlated with the

**Table 2. Summary of univariate and multivariate analyses of overall survival in 137 breast carcinoma patients**

Variable	Univariate		Multivariate
	P-value	P-value	Relative risk (95% CI)
Disease-free survival			
Lymph node status (positive/negative)	<b>0.001</b>	<b>0.001</b>	7.1 (2.4–21.5)
HER2 status (positive/negative)	<b>0.002</b>	<b>0.002</b>	4.0 (1.6–10.1)
Runx2 LI (99–0%)	<b>0.049</b>	<b>0.01</b>	1.02 (1.01–1.1)
Ki-67 LI (82–0%)	0.49		
Histological grade (3/1, 2)	0.56		
Tumor size (≥2.0 cm/<2.0 cm)	0.96		
Overall survival			
HER2 status (positive/negative)	<b>0.001</b>	<b>0.02</b>	4.0 (1.2–13.2)
Runx2 LI (99–0%)	<b>0.004</b>	<b>0.04</b>	1.03 (1.001–1.1)
Histological grade (3/1, 2)	<b>0.01</b>	0.5	
Lymph node status (positive/negative)	<b>0.03</b>	<b>0.02</b>	4.2 (1.1–1.68)
Ki-67 LI (82–0%)	<b>0.048</b>	0.29	
Tumor size (≥2.0 cm/<2.0 cm)	0.51		

Data considered significant ( $P < 0.05$ ) in the univariate analysis are shown in bold. CI, confidence interval; LI, labeling index.

## References

- Gnant M, Dubsy P, Fitzal F *et al*. Austrian Breast and Colorectal Cancer Study Group. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? *Clin Breast Cancer* 2009; **9**(Suppl 1): S18–27.
- Guise TA, Yin JJ, Taylor SD *et al*. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. *J Clin Invest* 1996; **98**: 1544–9.
- Burtis WJ, Brady TG, Orloff JJ *et al*. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. *N Engl J Med* 1990; **322**: 1106–12.
- Southby J, Kissin MW, Danks JA *et al*. Immunohistochemical localization of parathyroid hormone-related protein in breast cancer. *Cancer Res* 1990; **50**: 7710–6.
- Uy HL, Mundy GR, Boyce BF *et al*. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. *Cancer Res* 1997; **57**: 3194–9.
- Liu BY, Guo J, Lanske B, Divieti P, Kronenberg HM, Bringhurst FR. Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. *Endocrinology* 1998; **139**: 1952–64.
- Roodman GD. Biology of osteoclast activation in cancer. *J Clin Oncol* 2001; **19**: 3562–71.
- Guise TA, Mohammad KS, Clines G *et al*. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. *Clin Cancer Res* 2006; **12**: 6213s–6s.
- Suva LJ, Griffin RJ, Makhoul I. Mechanisms of bone metastases of breast cancer. *Endocr Relat Cancer* 2009; **16**: 703–13.
- Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. *Mol Cancer Ther* 2007; **6**: 2609–17.
- Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P. Biology of breast cancer bone metastasis. *Cancer Biol Ther* 2008; **7**: 3–9.
- Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. *Nat Rev Cancer* 2005; **5**: 376–87.
- Osato M, Asou N, Abdalla E *et al*. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. *Blood* 1999; **93**: 1817–24.
- Song W-J, Sullivan MG, Legare RD *et al*. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. *Nat Genet* 1999; **23**: 166–75.
- Ito K, Lim AC, Salto-Tellez M *et al*. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. *Cancer Cell* 2008; **14**: 226–37.
- Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. *Cell* 1997; **89**: 747–54.
- Komori T, Yagi H, Nomura S *et al*. Targeted disruption of *Cbfa1* results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* 1997; **89**: 755–64.
- Otto F, Thornell AP, Crompton T *et al*. *Cbfa1*, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development. *Cell* 1997; **89**: 765–71.
- Mundlos S, Otto F, Mundlos C *et al*. Mutations Involving the Transcription Factor CBFA1 Cause Cleidocranial Dysplasia. *Cell* 1997; **89**: 773–9.
- San Martin IA, Varela N, Gaete M *et al*. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells. *J Cell Physiol* 2009; **221**: 560–71.
- Pereira BP, Zhou Y, Gupta A *et al*. Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). *J Cell Physiol* 2009; **221**: 778–88.
- Inman CK, Sgore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. *J Biol Chem* 2003; **278**: 48684–9.
- Javed A, Barnes GL, Pratap J *et al*. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. *Proc Natl Acad Sci USA* 2005; **102**: 1454–9.
- Pratap J, Javed A, Languino LR *et al*. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. *Mol Cell Biol* 2005; **25**: 8581–91.
- Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. *Prostate* 2003; **56**: 13–22.
- Pratap J, Galindo M, Zaidi SK *et al*. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. *Cancer Res* 2003; **63**: 5357–62.
- Galindo M, Pratap J, Young DW *et al*. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. *J Biol Chem* 2005; **280**: 20274–85.
- Inman CK, Li N, Shore P. Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. *Mol Cell Biol* 2005; **25**: 3182–93.
- Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. *J Cell Biochem* 2005; **96**: 484–9.

## Acknowledgments

The authors appreciate the skillful technical assistance of Mr Katsuhiko Ono and Ms Miki Mori (Department of Pathology, Tohoku University School of Medicine).

## Disclosure Statement

The authors have no conflict of interest.

- 30 Pratap J, Wixted JJ, Gaur T *et al.* Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. *Cancer Res* 2008; **68**: 7795–802.
- 31 Zelzer E, Glotzer DJ, Hartmann C *et al.* Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. *Mech Dev* 2001; **106**: 97–106.
- 32 Selvamurugan N, Kwok S, Partridge NC. Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. *J Biol Chem* 2004; **279**: 27764–73.
- 33 Barnes GL, Javed A, Waller SM *et al.* Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. *Cancer Res* 2003; **63**: 2631–7.
- 34 Das K, Leong DT, Gupta A *et al.* Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. *Eur J Cancer* 2009; **45**: 2239–48.
- 35 Brown SA, Guise TA. Cancer treatment-related bone disease. *Crit Rev Eukaryot Gene Expr* 2009; **19**: 47–60.
- 36 Miki Y, Suzuki T, Sasano H. Aromatase inhibitor and bone. *Biomed Pharmacother* 2007; **61**: 540–2.
- 37 Fogelman I, Blake GM, Blamey R *et al.* Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). *Osteoporos Int* 2003; **14**: 1001–6.
- 38 Coates AS, Keshaviah A, Thurlimann B *et al.* Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. *J Clin Oncol* 2007; **25**: 486–92.
- 39 Howell A, Cuzick J, Baum M *et al.* Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. *Lancet* 2005; **365**: 60–2.
- 40 Mak IW, Cowan RW, Popovic S, Colterjohn N, Singh G, Ghert M. Upregulation of MMP-13 via Runx2 in the stromal cell of Giant Cell Tumor of bone. *Bone* 2009; **45**: 377–86.
- 41 Goldhirsch A, Glick JH, Gelber RD *et al.* Meeting highlights: international expert consensus on the primary therapy of early breast cancer. *Ann Oncol* 2005; **10**: 1569–83.
- 42 Birner P, Oberhuber G, Stani J *et al.* Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. *Clin Cancer Res* 2001; **7**: 1669–75.
- 43 Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987; **235**: 177–82.
- 44 Risau W. Mechanisms of angiogenesis. *Nature* 1997; **386**: 671–4.
- 45 Bergers G, Brekken R, McMahon G *et al.* Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. *Nat Cell Biol* 2000; **2**: 737–44.
- 46 Itoh T, Tanioka M, Matsuda H *et al.* Experimental metastasis is suppressed in MMP-9-deficient mice. *Clin Exp Metastasis* 1999; **17**: 177–81.
- 47 Nakamura T, Imai Y, Matsumoto T *et al.* Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. *Cell* 2007; **130**: 811–23.
- 48 Cenci S, Weitzmann MN, Roggia C *et al.* Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. *J Clin Invest* 2000; **106**: 1229–37.
- 49 Riggs BL. The mechanisms of estrogen regulation of bone resorption. *J Clin Invest* 2000; **106**: 1203–4.
- 50 Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. *Immunol Rev* 2005; **208**: 207–27.
- 51 Casimiro S, Guise TA, Chirgwin J. The critical role of the bone microenvironment in cancer metastases. *Mol Cell Endocrinol* 2009; **310**: 71–81.



Contents lists available at ScienceDirect

# Molecular and Cellular Endocrinology

journal homepage: [www.elsevier.com/locate/mce](http://www.elsevier.com/locate/mce)



## Review

# Steroid sulfatase and estrogen sulfotransferase in human carcinomas

Takashi Suzuki<sup>a,\*</sup>, Yasuhiro Miki<sup>b</sup>, Yasuhiro Nakamura<sup>b</sup>, Kiyoshi Ito<sup>c</sup>, Hironobu Sasano<sup>b</sup>

<sup>a</sup> Department of Pathology and Histotechnology, Tohoku University, Graduate School of Medicine, 2-1 Seiryō-machi, Aoba-ku, Sendai 980-8575, Japan

<sup>b</sup> Department of Anatomic Pathology, Tohoku University, Graduate School of Medicine, Sendai 980-8575, Japan

<sup>c</sup> Department of Obstetrics and Gynecology, Tohoku University, Graduate School of Medicine, Sendai 980-8575, Japan

## ARTICLE INFO

### Article history:

Received 5 December 2009

Received in revised form 6 October 2010

Accepted 1 November 2010

### Key words:

Carcinoma

Estrogen

Estrogen sulfotransferase

Steroid sulfatase

## ABSTRACT

Estrogens are closely involved in the development of hormone-dependent carcinomas. Estrone is locally produced from circulating inactive estrone sulfate by steroid sulfatase (STS), while estrone is inversely inactivated into estrone sulfate by estrogen sulfotransferase (EST). Recent studies suggested importance of this STS pathway in various human carcinomas. Therefore, in this review, we summarized recent results of STS and EST in several estrogen-dependent carcinomas. STS and EST expressions were detected in the breast and endometrial carcinomas, and activation of STS pathway due to increment in STS and/or decrement in EST expressions plays important role in their estrogen-dependent growth. STS expression was also reported in the ovarian and prostate carcinomas. STS/EST status was associated with intratumoral estrogen level in the colon carcinoma, and STS-negative/EST-positive colon carcinoma patients had longer survival. Therefore, STS pathway and estrogen actions may play an important role in the development of these carcinomas, and further investigations are required.

© 2010 Elsevier Ireland Ltd. All rights reserved.

## Contents

1. Introduction .....	00
2. STS and EST .....	00
2.1. STS .....	00
2.2. EST .....	00
3. STS and EST in the breast carcinoma .....	00
4. STS and EST in other carcinomas .....	00
4.1. Endometrial carcinoma .....	00
4.2. Ovarian carcinoma .....	00
4.3. Prostate carcinoma .....	00
4.4. Colon carcinoma .....	00
References .....	00

## 1. Introduction

It is well known that estrogens are closely involved in the development of hormone-dependent carcinomas. Estrogens actions are mediated through an interaction with the estrogen receptors (ERs). ER is expressed in a great majority of the breast carcinoma, the most representative estrogen-dependent malignancy. However, a great majority of breast carcinomas arise after menopause when ovaries ceased to be functional, and ER expression is not neces-

sarily associated with plasma concentrations of estrogens in these patients.

Recent studies have demonstrated that estrogens are locally produced from circulating inactive steroids in the breast carcinomas by steroid sulfatase (STS) and aromatase (Suzuki et al., 2005) (Fig. 1). The former pathway converts to estrone from circulating estrone sulfate by STS, while estrone is inversely inactivated into estrone sulfate by estrogen sulfotransferase (EST). In the latter, aromatase produces estrone from circulating androstendione. Estrone is subsequently converted to a potent estrogen, estradiol, by reductive 17 $\beta$ -hydroxysteroid dehydrogenases (17 $\beta$ HSDs). 14 isozymes of 17 $\beta$ HSD have been currently identified, and 17 $\beta$ -reduction (17 $\beta$ HSD1, 7, 12 etc) or oxidation (17 $\beta$ HSD2, 4, 14 etc)

\* Corresponding author. Tel.: +81 22 717 7947; fax: +81 22 717 7947.

E-mail address: [t-suzuki@patholo2.med.tohoku.ac.jp](mailto:t-suzuki@patholo2.med.tohoku.ac.jp) (T. Suzuki).




Fig. 1. Scheme representing *in situ* production of estrogens in the breast carcinoma tissue which is currently postulated. STS; steroid sulfatase, EST; estrogen sulfotransferase, 17βHSD1; 17β-hydroxysteroid dehydrogenase type 1, and ER; estrogen receptor.

of estrogens is catalyzed by different 17βHSD isozymes. The reductive 17βHSD pathway is dominant in the breast carcinoma, and 17βHSD1 enzyme is considered to play the most important role in the enhanced conversion of estrone into estradiol in the breast carcinoma (Nagasaki et al., 2009).

Estradiol concentration in the breast carcinoma tissue was not significantly different regardless of the menopausal status of patients (Pasqualini, 2004), and a large proportion, *i.e.*, approximately 75% before menopause and close to 100% after menopause, of biologically active estrogens is considered to be locally produced in the breast carcinoma (Labrie et al., 2003). Comparison of STS and aromatase activities has been previously examined in the breast carcinoma by several groups. For instances, Santner et al. (1984) found that as much as 10-fold more estrone could originate from estrone sulfate *via* the STS pathway than from androstenedione by the aromatase route, and Pasqualini et al. (1996) showed that STS activity measured by estrone production from estrone sulfate was 50–200 times greater than aromatase activity evaluated by testosterone as a substrate. These data are suggestive of relative importance of STS pathway in the pathogenesis of the breast carcinoma (Reed et al., 2005).

ER is expressed in various human carcinoma tissues, including endometrial, ovarian, prostate and colon carcinomas, in addition to breast carcinoma. Its significance, however, has not been fully elucidated, because some carcinomas are not necessarily considered targets for estrogens. However, an increasing body of evidence suggests that *in situ* production of estrogen through the STS pathway may play an important role in the development of these carcinomas, and the presence of STS may lead to therapeutic potential in a selective group of the carcinomas. In order to obtain a better understanding of local actions of estrogens, it becomes very important to examine the status of STS and EST in these carcinomas. Therefore, in this review, we summarized results of recent studies on STS and EST in several estrogen-dependent carcinomas, and discuss the significance of STS pathway in these carcinomas.

## 2. STS and EST

### 2.1. STS

Sulfatase family catalyzes hydrolysis of sulfate ester bonds of a wide variety of substrates, and 17 human sulfatase proteins and their corresponding genes have been identified (Ghosh, 2007). STS belongs to the sulfatase family, and also named as arylsulfatase C (ARSC). STS hydrolyzes several sulfated steroids, such as estrone

sulfate and dehydroepiandrosterone (DHEA) sulfate (Reed et al., 2005). STS is a microsomal enzyme and is an integral membrane protein of endoplasmic reticulum. Human STS gene is localized on the X-chromosome and mapped in Xp22.3-Xpter, and consists of 10 exons (Reed et al., 2005). STS is expressed in several tissues including the placenta and skin (Ghosh, 2007; Selcer et al., 2007), although it is also true that STS immunoreactivity was negligible in many human tissues (Miki et al., 2002). Mutations in the STS gene and subsequent inactive enzyme have been associated with X-linked ichthyosis (Ghosh, 2004; Reed et al., 2005). Several single nucleotide polymorphisms (SNPs) have been reported in the promoter region and exons of STS gene (Goodarzi et al., 2007; Udler et al., 2009; Matsumoto et al., 2010). Some of these are suggested to possibly regulate the transcriptional and/or enzymatic activities of STS (Matsumoto et al., 2010), but their significance remains unclear.

Six different promoters were detected to drive STS expression, giving rise to transcripts with unique first exons (Valle et al., 2006, 2007), and exon 1a was associated with the promoter that drives expression in the placenta. In addition, Nardi et al. (2009) reported two additional alternatively spliced transcripts in human tissues and cell lines. On the other hand, Zaichuk et al. (2007) demonstrated that STS transcription was up-regulated by estradiol through the binding of ER to estrogen responsive elements (EREs) located in the promoter regions, which resulted in driving 1a and 1b transcripts in the breast carcinoma. Therefore, STS expression may be regulated by different promoters according to the cellular functions and/or tissues. Interleukin (IL) 6 and tumor necrosis factor (TNF) α were reported to stimulate STS activity in breast carcinoma cells, possibly *via* a post-transcriptional modification of the enzyme (Newman et al., 2000).

Tsunoda et al. (2006) found that serum levels of estrogens, such as estrone, estrone sulfate, estradiol, and estradiol sulfate, were decreased after operation in postmenopausal patients with markedly STS positive breast carcinoma. In addition, Kirilovas et al. (2007) reported that STS activity in ovarian tumors was correlated with the serum estradiol level. These findings may suggest that intratumoral STS activity partly affects plasma estrogen concentration. However, human liver represents a major site for metabolism of circulating estrogens, and further examinations are required.

### 2.2. EST

The cytosolic sulfotransferases (SULTs) catalyze the transfer of the sulfonyl group to an acceptor substrate including phenols, estrogens, hydroxysteroids, arylamines, primary alcohols and iodothyronines. In human, three families of SULTs have been characterized: SULT1 family included 8 subfamilies (A1, A2, A3, A4, B1, C2, C4, and E1), SULT2 family included 2 subfamilies (A1 and B1), and SULT4 family (A1) (Pasqualini, 2009). Among these SULTs, SULT1E1 has the most marked sulfating activity for estrogens (Adjei et al., 2003; Hui et al., 2008). Therefore, SULT1E1 regulates the STS pathway and subsequently local estrogen levels in human tissues, and termed EST. In addition, EST is the only sulfotransferase that displays affinity for estradiol in a physiological concentration range (Zhang et al., 1998; Pasqualini, 2009).

EST gene is localized on chromosome 4q13.2, and EST protein consists of 294 amino acids. Miki et al. (2002) demonstrated that EST mRNA expression was detected in various human tissues, and suggested that EST was involved in protecting peripheral tissues from possible excessive estrogenic effects. To date, more than 20 SNPs have been found in EST gene (Iida et al., 2001; Adjei et al., 2003), and SNP IVS4-1653 (rs3775775) was significantly associated with increased recurrence of breast carcinoma (Choi et al., 2005). A positive association between EST SNP and risk of endometrial cancer has been also reported (Rebeck et al., 2006; Hirata et al., 2008). EST expression is controlled by progesterone in nor-



mal endometrium (Dassen et al., 2007), but little is currently known on the regulatory mechanism of EST.

### 3. STS and EST in the breast carcinoma

Estrone sulfate has a relatively long half-life in the peripheral blood, and the level of estrone sulfate is 5–10 times higher than that of unconjugated estrogens such as estrone, estradiol and estriol, during the menstrual cycle and in postmenopausal women (Pasqualini, 2004). Tissue concentration of estradiol in the breast carcinoma was 5-fold higher than in plasma in premenopausal women, and 23-fold higher in postmenopausal women (Pasqualini, 2004). Estradiol concentration was also 2-fold higher in breast carcinoma tissues than in the areas considered as morphologically normal (Chetrite et al., 2000). STS mainly catalyzes estrone sulfate to estrone in breast carcinoma (Fig. 1), which immensely contributes to the intratumoral estrogen production.

STS enzyme activity was detected in the great majority of breast carcinomas (Evans et al., 1994). STS mRNA expression was higher in breast carcinoma tissues than that in normal breast tissues, and it was significantly associated with the breast carcinoma progression and poor clinical outcome of the patients (Utsumi et al., 1999; Miyoshi et al., 2003; Suzuki et al., 2009). Irahara et al. (2006) reported that both STS and 17 $\beta$ HSD1 mRNAs were up-regulated in soft tissue metastases of breast carcinoma compared to those in primary tumors, suggesting importance of STS associated with local estrogen production in metastatic sites of the breast carcinoma. STS immunoreactivity was detected in carcinoma cells in 60–90% of breast carcinoma cases (Saeki et al., 1999; Suzuki et al., 2003; Yamamoto et al., 2003; Tsunoda et al., 2006) (Fig. 2(A)). STS immunoreactivity was frequently detected in postmenopausal patients (Tsunoda et al., 2006), and was significantly associated with tumor size and increased risk of recurrence (Suzuki et al., 2003). Several groups are currently developing STS inhibitors, and results of a phase I study suggested that STS inhibitor may be effective in estrogen-dependent breast carcinomas including those progressed on aromatase inhibitors (Stanway et al., 2006).

Expression of STS mRNA was significantly higher in ductal carcinoma *in situ* (DCIS) than the non-neoplastic breast tissue, and STS immunoreactivity was detected in 54% of DCIS tissues (Shibuya et al., 2008). Therefore, *in situ* production of estrogens by STS may also play important roles in DCIS as a precursor lesion of invasive ductal carcinoma.

The concentration of estrone sulfate was significantly (approximately 10 times) higher in breast carcinoma tissues than that in plasma levels (Pasqualini, 2004), and EST enzyme activity was detected in breast carcinoma tissues and normal breast tissues (Tseng et al., 1983). MCF-7 breast carcinoma cells transfected with EST demonstrated much lower estrogen-stimulated DNA synthesis or cell proliferation than control MCF-7 cells that did not possess EST (Qian et al., 1998; Falany et al., 2002). In addition, Fu et al. (2009) examined EST mRNA expression in MCF-10A-derived lineage cell culture model, and reported that EST was abundantly expressed in FCF-10A and preneoplastic MCF-10AT1 cell lines, but was markedly repressed in neoplastic MCF-10A-derived cell lines as well as in MCF-7 cells. Therefore, the loss of EST expression during the process of carcinogenesis may represent a possible important factor in increasing local estrogen production in the breast carcinoma as well as the induction of STS expression.

EST enzyme activity and its mRNA expression were detected in breast carcinoma tissues (Tseng et al., 1983; Suzuki et al., 2003; Yoshimura et al., 2004; Suzuki et al., 2009). EST mRNA expression was detected in intratumoral stromal cells and adipocytes adjacent to the carcinoma in addition to the breast carcinoma cells. Suzuki et al. (2003, 2009) reported that EST mRNA level was high in non-malignant breast tissues. EST immunoreactivity was detected in





Fig. 2. STS (A) and EST (B) immunoreactivities in the breast carcinoma. Both immunoreactivities were detected in the cytoplasm of carcinoma cells. Bar = 100  $\mu$ m, respectively.

the carcinoma cells in 40% of invasive breast carcinomas by Suzuki et al. (2003) or 80% of those by Hudelist et al. (2008), and it was also present in the epithelial cells of normal mammary glands (Suzuki et al., 2003) and DCIS (Hudelist et al., 2008) (Fig. 2(B)). EST immunoreactivity was inversely correlated with tumor size or lymph node status in the invasive breast carcinoma, and was also significantly associated with a decreased risk of recurrence or improved prognosis of the patients (Suzuki et al., 2003). These findings may be due to the fact that EST-negative breast carcinomas result in an increment of intratumoral estrogen concentrations, which subsequently results in an increased recurrence and/or poor prognosis in these patients.

Because sulfated steroid conjugates, such as estrone sulfate, carry a net negative charge at physiological pH, their transfer across cell membranes is considered to be carrier mediated. Sulfated steroids have been identified as substrates for a superfamily of organic anion transporting polypeptides (OATPs) (Hagenbuch and Meier, 2003). Miki et al. (2006) demonstrated that OATP-A was a target gene of steroid and xenobiotic receptor (SXR) and SXR immunoreactivity was positively correlated with STS immunoreactivity in the breast carcinoma, suggesting that estrone sulfate may be transported into breast carcinoma cells by OATP-A and subsequently transformed into estrone by STS. In addition, Muto et al. (2007) reported that other member of OATPs, liver-specific organic anion transporter-2 (LST-2), expressed in the breast carcinoma, and its immunoreactivity was significantly associated with a decreased risk of recurrence and improved prognosis in 102 breast carcinoma cases. When we further analyzed an association between LST-





**Fig. 3.** Disease-free (A) and overall (B) survival of 102 patients with breast carcinoma according to LST-2/STS status (Kaplan–Meier method). LST-2/STS status was evaluated by immunohistochemistry. A+/+ group (i.e., breast carcinoma positive for both LST-2 and STS) was significantly associated with an increased risk of recurrence ( $P < 0.01$  by a log-rank test). Similar tendency was detected in the overall survival (B), although  $P$  value was not calculated because no patient had died in the +/- group in this study. Original data were taken from Muto et al. (2007).

2/STS immunohistochemical status and clinical outcomes of these patients, a breast carcinoma group positive for both LST-2 and STS did demonstrate the worst prognosis (Fig. 3). Therefore, LST-2 may be an important regulator for STS pathway in the breast carcinoma by possibly increasing intracellular concentration or availability of the precursor estrone sulfate.

Intratumoral estrogen levels are regulated by complex enzyme systems in the breast carcinoma (Fig. 1). Recently, Lønning et al. (2009) demonstrated a significantly increased estradiol concentration in ER-positive breast carcinoma compared to normal tissue, but not in ER-negative cases, while the estrone level was significantly reduced in the carcinoma tissue regardless of ER status. On the other hand, intratumoral concentration of estrone sulfate was significantly higher in ER-positive postmenopausal breast carcinoma and ER-negative breast carcinoma than the normal tissue. Therefore, high concentration of estradiol in the breast carcinoma may be caused by not only enhanced local estrogen production but also alternative mechanisms as receptor ligand binding or alteration of intratumoral estrogen dynamics including the enhanced conversion of estrone to estradiol by 17 $\beta$ HSD system (Lønning et al., 2009).

#### 4. STS and EST in other carcinomas

##### 4.1. Endometrial carcinoma

Endometrium is one of the target tissues of estrogen, and endometrial carcinoma is known as an estrogen-dependent malignancy as well as the breast carcinoma.

Endometrial carcinoma frequently expresses ER, and most cases occur in postmenopausal women. Estradiol level in the endometrial carcinoma tissue was significantly higher than normal endometrium (1.9-fold in premenopausal patients, and 1.5-fold in postmenopausal patients (Berstein et al., 2003)), and high concentration of estrogens is maintained in endometrial carcinoma tissues regardless of menopausal status of the patients.

STS immunoreactivity was negative in the normal endometrium, but that of EST was detected in glandular epithelial cells in the secretory phase (Utsunomiya et al., 2004). STS activity was significantly higher in the endometrial carcinoma than in normal endometrial tissues (Abulafia et al., 2009). Smuc and Rizner (2009) however, recently reported that EST mRNA expression in endometrial carcinoma was significantly decreased compared to the paired normal endometrium, whereas STS mRNA level was not significantly different between these groups. Both STS and EST immunoreactivities were detected in 86% and 29% of endometrial carcinomas, respectively, and STS/EST ratio was significantly associated with poor prognosis of the endometrial carcinoma patients (Utsunomiya et al., 2004). Therefore, a possible activation of STS pathway due to increment in STS and/or decrement in EST expressions may also play important roles in the estrogen-dependent growth of endometrial carcinoma, as in breast carcinomas. Recently, Foster et al. (2008) demonstrated an inhibition of endometrial carcinoma growth by STS inhibitor using a hormone-dependent endometrial xenograft model in ovariectomized mice.

##### 4.2. Ovarian carcinoma

Ovarian carcinoma is mainly originated from the surface epithelium, and has poor prognosis because of frequent occult metastasis in the peritoneal cavity and detection at the advanced clinical stage. Previous studies have suggested an association between estrogens and initiation and/or progression of ovarian carcinoma, although some inconsistent findings have been reported. This hypothesis is partially supported by recent large population-based case-control study and meta-analysis of estrogen-based hormone replacement therapy (HRT), in which incidence of ovarian carcinoma was statistically increased in both current and ever users (O'Connor, 2006; Ragonese et al., 2006).

STS enzymatic activity was also detected in the ovarian carcinoma (Milewich and Porter, 1987). Chura et al. (2009) demonstrated that ovarian cancer patients with higher STS activity were significantly associated with shorter progression-free survival than those with STS lower activity. STS immunoreactivity was detected in 70% of ovarian clear cell adenocarcinoma (Okuda et al., 2001). Very recently, Day et al. (2009) demonstrated that STS enzymatic activity in ER-positive ovarian carcinoma cell line OVCAR-3 was inhibited by STS inhibitor STX64, suggesting its therapeutic potential also for ovarian carcinoma. It awaits further investigation to clarify the importance of STS pathway in the ovarian carcinoma.

##### 4.3. Prostate carcinoma

It is well known that androgens play a pivotal role in the pathogenesis of prostate carcinoma through androgen receptor. STS catalyzes DHEA from DHEA sulfate, and it possibly play important role in the intratumoral androgen production (Day et al., 2009). Estrogens are, however, generally considered an important factor associated with cell proliferation of prostate carcinoma cells (Härkönen and Mäkelä, 2004).

STS activity in prostate carcinoma cells produced significant levels of estrone and estradiol when these cells were treated with estrone sulfate (Nakamura et al., 2006). Giton et al. (2008) demon-

strated that serum estrone sulfate concentration was significantly higher in prostate cancer patients than that from age-matched control, and was significantly higher in prostate carcinoma patients associated with a poor prognosis. They suggested that higher serum estrone sulfate would lead to an increment of local estrogen production in the prostate carcinoma by STS pathway. Kapoor and Sheng (2008) examined biological functions of EST in the prostate carcinoma cells, and demonstrated that EST significantly repressed ERE activation by estradiol through ER.

STS immunoreactivity was not detected in non-neoplastic prostate tissues (Nakamura et al., 2006), while EST mRNA and protein were detected in the benign prostatic hyperplasia (Takase et al., 2007). Both STS and EST mRNA was detected in prostate carcinoma tissues, and STS and EST immunoreactivities were positive in 85% and 75% of prostate carcinomas, respectively (Nakamura et al., 2006). Therefore, STS and EST may regulate *in situ* production and action of estrogens in the prostate carcinoma tissues.

#### 4.4. Colon carcinoma

A great majority of colon carcinomas expresses ER $\beta$  (Wong et al., 2005), and a number of observational studies (Grodstein et al., 1999; Newcomb et al., 2007) and randomized trials (Anderson et al., 2004) have demonstrated that HRT affects the incidence of colon cancer in postmenopausal women. Therefore, estrogens are considered to be involved in the pathogenesis of colon carcinoma, but the biological and/or clinical significance of estrogens has remained largely unclear in human colon carcinoma.

Recently, Sato et al. (2009) measured intratumoral concentrations of estrogens in colon carcinomas, and tissue concentrations of total estrogens (*i.e.*, estrone and estradiol) and estrone were significantly higher in colon carcinoma than in non-neoplastic colonic mucosa, and higher intratumoral concentrations of total estrogens and estrone were significantly correlated with poorer prognosis of the patients. In addition, intratumoral concentration of total estrogens in the colon carcinoma was significantly associated with STS/EST immunohistochemical status, but not with aromatase immunoreactivity (Sato et al., 2009). Immunoreactivities for STS and EST were detected in 61% and 44% of the colon carcinomas, and STS-negative and EST-positive colon carcinoma patients had significantly longer survival (Sato et al., 2009). Therefore, estrogens are postulated to be locally produced by STS pathway and may contribute to the progression of colon carcinoma, and STS inhibitors may be clinically effective in a selective groups of colon carcinoma patients. However, these findings are not necessarily consistent with previous reports that HRT reduced the risk of colon cancer (Grodstein et al., 1999) and improved survival from colon cancer (Mandelson et al., 2003). Therefore, further examinations are required to clarify the significance of estrogen and STS pathway in the colon carcinoma.

#### References

Abulafia, O., Lee, Y.C., Wagreich, A., Economos, K., Serur, E., Nacharaju, V.L., 2009. Sulfatase activity in normal and neoplastic endometrium. *Gynecol. Obstet. Invest.* 67, 57–60.

Adjei, A.A., Thomae, B.A., Prondzinski, J.L., Eckloff, B.W., Wieben, E.D., Weinshilboum, R.M., 2003. Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. *Br. J. Pharmacol.* 139, 1373–1382.

Anderson, G.L., Limacher, M., Assaf, A.R., Bassford, T., Beresford, S.A., Black, H., Bonds, D., Brunner, R., Brzyski, R., Caan, B., Chlebowski, R., Curb, D., Gass, M., Hays, J., Heiss, G., Hendrix, S., Howard, B.V., Hsia, J., Hubbell, A., Jackson, R., Johnson, K.C., Judd, H., Kotchen, J.M., Kuller, L., LaCroix, A.Z., Lane, D., Langer, R.D., Lasser, N., Lewis, C.E., Manson, J., Margolis, K., Ockene, J., O'Sullivan, M.J., Phillips, L., Prentice, R.L., Ritenbaugh, C., Robbins, J., Rossouw, J.E., Sarto, G., Stefanick, M.L., Van Horn, L., Wactawski-Wende, J., Wallace, R., Wassertheil-Smolter, S., 2004. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 291, 1701–1712.

Berstein, L.M., Tchernobrovkina, A.E., Gamajunova, V.B., Kovalevskij, A.J., Vasilyev, D.A., Chepik, O.F., Turkevitch, E.A., Tsyrlina, E.V., Maximov, S.J., Ashrafian, L.A., Thijssen, J.H., 2003. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. *J. Cancer Res. Clin. Oncol.* 129, 245–249.

Chetrite, G.S., Cortes-Prieto, J., Philippe, J.C., Wright, F., Pasqualini, J.R., 2000. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. *J. Steroid Biochem. Mol. Biol.* 72, 23–27.

Choi, J.Y., Lee, K.M., Park, S.K., Noh, D.Y., Ahn, S.H., Chung, H.W., Han, W., Kim, J.S., Shin, S.G., Jang, I.J., Yoo, K.Y., Hirvonen, A., Kang, D., 2005. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. *Cancer Epidemiol. Biomarkers Prev.* 14, 1090–1095.

Chura, J.C., Blomquist, C.H., Ryu, H.S., Argenta, P.A., 2009. Estrone sulfatase activity in patients with advanced ovarian cancer. *Gynecol. Oncol.* 112, 205–209.

Dassen, H., Punyadeera, C., Kamps, R., Delvoux, B., Van Langendonck, A., Donnez, J., Husen, B., Thole, H., Dunselman, G., Groothuis, P., 2007. Estrogen metabolizing enzymes in endometrium and endometriosis. *Hum. Reprod.* 22, 3148–3158.

Day, J.M., Purohit, A., Tutill, H.J., Foster, P.A., Woo, L.W., Potter, B.V., Reed, M.J., 2009. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. *Ann. N. Y. Acad. Sci.* 1155, 80–87.

Evans, T.R., Rowlands, M.G., Law, M., Coombes, R.C., 1994. Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. *Br. J. Cancer* 69, 555–561.

Falany, J.L., Macrina, N., Falany, C.N., 2002. Regulation of MCF-7 breast cancer cell growth by beta-estradiol sulfation. *Breast Cancer Res. Treat.* 74, 167–176.

Foster, P.A., Reed, M.J., Purohit, A., 2008. Recent developments of steroid sulfatase inhibitors as anti-cancer agents. *Anticancer Agents Med. Chem.* 8, 732–738.

Fu, J., Weise, A.M., Falany, J.L., Falany, C.N., Thibodeau, B.J., Miller, F.R., Kocarek, T.A., Runge-Morris, M., 2009. Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. *Breast Cancer Res. Treat.* (Epub ahead of print).

Ghosh, D., 2004. Mutations in X-linked ichthyosis disrupt the active site structure of estrone/DHEA sulfatase. *Biochim. Biophys. Acta* 1739, 1–4.

Ghosh, D., 2007. Human sulfatases: a structural perspective to catalysis. *Cell. Mol. Life Sci.* 64, 2013–2022.

Giton, F., de la Taille, A., Allory, Y., Galons, H., Vacherot, F., Soyeux, P., Abbou, C.C., Loric, S., Cussenot, O., Raynaud, J.P., Fiet, J., 2008. Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCA). *J. Steroid Biochem. Mol. Biol.* 109, 158–167.

Goodarzi, M.O., Antoine, H.J., Azziz, R., 2007. Genes for enzymes regulating dehydroepiandrosterone sulfonation are associated with levels of dehydroepiandrosterone sulfate in polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 92, 2659–2664.

Grodstein, F., Newcomb, P.A., Stampfer, M.J., 1999. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. *Am. J. Med.* 106, 574–582.

Hagenbuch, B., Meier, P.J., 2003. The superfamily of organic anion transporting polypeptides. *Biochim. Biophys. Acta* 1609, 1–18.

Härkönen, P.L., Mäkelä, S.J., 2004. Role of estrogens in development of prostate cancer. *J. Steroid Biochem. Mol. Biol.* 92, 297–305.

Hirata, H., Hinoda, Y., Okayama, N., Suehiro, Y., Kawamoto, K., Kikuno, N., Rabban, J.T., Chen, L.M., Dahiya, R., 2008. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. *Cancer* 112, 1964–1973.

Hudelist, G., Wülfing, P., Kersting, C., Burger, H., Mattsson, B., Czerwenka, K., Kubista, E., Gschwantler-Kaulich, D., Fink-Retter, A., Singer, C.F., 2008. Expression of aromatase and estrogen sulfotransferase in preinvasive and invasive breast cancer. *J. Cancer Res. Clin. Oncol.* 134, 67–73.

Hui, Y., Yasuda, S., Liu, M.Y., Wu, Y.Y., Liu, M.C., 2008. On the sulfation and methylation of catecholestrogens in human mammary epithelial cells and breast cancer cells. *Biol. Pharm. Bull.* 31, 769–773.

Iida, A., Sekine, A., Saito, S., Kitamura, Y., Kitamoto, T., Osawa, S., Mishima, C., Nakamura, Y., 2001. Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes. *J. Hum. Genet.* 46, 225–240.

Irahara, N., Miyoshi, Y., Taguchi, T., Tamaki, Y., Noguchi, S., 2006. Quantitative analysis of aromatase, sulfatase and 17 $\beta$ -HSD(1) mRNA expression in soft tissue metastases of breast cancer. *Cancer Lett.* 243, 23–31.

Kapoor, R., Sheng, J.J., 2008. Transfection of human prostate cancer CA-HPV-10 cells with cytosolic sulfotransferase SULT1E1 affects estrogen signaling and gene transcription. *Drug Metab. Dispos.* 36, 316–321.

Kirilovas, D., Schedvins, K., Naessén, T., Von Schoultz, B., Carlström, K., 2007. Conversion of circulating estrone sulfate to 17 $\beta$ -estradiol by ovarian tumor tissue: a possible mechanism behind elevated circulating concentrations of 17 $\beta$ -estradiol in postmenopausal women with ovarian tumors. *Gynecol. Endocrinol.* 23, 25–28.

Labrie, F., Luu-The, V., Labrie, C., Belanger, A., Simard, J., Lin, S.X., Pelletier, G., 2003. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. *Endocr. Rev.* 24, 152–182.

Lønning, P.E., Helle, H., Duong, N.K., Ekse, D., Aas, T., Geisler, J., 2009. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. *J. Steroid Biochem. Mol. Biol.* 117, 31–41.

Mandelson, M.T., Miglioretti, D., Newcomb, P.A., Harrison, R., Potter, J.D., 2003. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. *Cancer Causes Control* 14, 979–984.

- Matsumoto, J., Ariyoshi, N., Ishii, I., Kitada, M., 2010. Six novel single nucleotide polymorphisms of the steroid sulfatase gene in a Japanese population. *Drug Metab. Pharmacokinet.* 25, 403–407.
- Miki, Y., Nakata, T., Suzuki, T., Darnel, A.D., Moriya, T., Kaneko, C., Hidaka, K., Shiotsu, Y., Kusaka, H., Sasano, H., 2002. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. *J. Clin. Endocrinol. Metab.* 87, 5760–5768.
- Miki, Y., Suzuki, T., Kitada, K., Yabuki, N., Shibuya, R., Moriya, T., Ishida, T., Ohuchi, N., Blumberg, B., Sasano, H., 2006. Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. *Cancer Res.* 66, 535–542.
- Milewich, L., Porter, J.C., 1987. In situ steroid sulfatase activity in human epithelial carcinoma cells of vaginal, ovarian, and endometrial origin. *J. Clin. Endocrinol. Metab.* 65, 164–169.
- Miyoshi, Y., Ando, A., Hasegawa, S., Ishitobi, M., Taguchi, T., Tamaki, Y., Noguchi, S., 2003. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. *Clin. Cancer Res.* 9, 2288–2293.
- Muto, M., Onogawa, T., Suzuki, T., Ishida, T., Rikiyama, T., Katayose, Y., Ohuchi, N., Sasano, H., Abe, T., Unno, M., 2007. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. *Cancer Sci.* 98, 1570–1576.
- Nagasaki, S., Miki, Y., Akahira, J., Suzuki, T., Sasano, H., 2009. 17beta-hydroxysteroid dehydrogenases in human breast cancer. *Ann. N. Y. Acad. Sci.* 1155, 25–32.
- Nakamura, Y., Suzuki, T., Fukuda, T., Ito, A., Endo, M., Moriya, T., Arai, Y., Sasano, H., 2006. Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. *Prostate* 66, 1005–1012.
- Nardi, A., Pomari, E., Zamboni, D., Belvedere, P., Colombo, L., Dalla Valle, L., 2009. Transcriptional control of human steroid sulfatase. *J. Steroid Biochem. Mol. Biol.* 115, 68–74.
- Newcomb, P.A., Zheng, Y., Chia, V.M., Morimoto, L.M., Doria-Rose, V.P., Templeton, A., Thibodeau, S.N., Potter, J.D., 2007. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. *Cancer Res.* 67, 7534–7539.
- Newman, S.P., Purohit, A., Ghilchik, M.W., Potter, B.V., Reed, M.J., 2000. Regulation of steroid sulphatase expression and activity in breast cancer. *J. Steroid Biochem. Mol. Biol.* 75, 259–264.
- O'Connor, M.I., 2006. Osteoarthritis of the hip and knee: sex and gender differences. *Orthop. Clin. North Am.* 37, 559–568.
- Okuda, T., Saito, H., Sekizawa, A., Shimizu, Y., Akamatsu, T., Kushima, M., Yanaihara, T., Okai, T., Farina, A., 2001. Steroid sulfatase expression in ovarian clear cell adenocarcinoma: immunohistochemical study. *Gynecol. Oncol.* 82, 427–434.
- Pasqualini, J.R., 2004. The selective estrogen enzyme modulators in breast cancer: a review. *Biochim. Biophys. Acta* 1654, 123–143.
- Pasqualini, J.R., 2009. Estrogen sulfotransferases in breast and endometrial cancers. *Ann. N. Y. Acad. Sci.* 1155, 88–98.
- Pasqualini, J.R., Chetrite, G., Blacker, C., Feinstein, M.C., Delalonde, L., Talbi, M., Maloche, C., 1996. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. *J. Clin. Endocrinol. Metab.* 81, 1460–1464.
- Qian, Y., Deng, C., Song, W.C., 1998. Expression of estrogen sulfotransferase in MCF-7 cells by cDNA transfection suppresses the estrogen response: potential role of the enzyme in regulating estrogen-dependent growth of breast epithelial cells. *J. Pharmacol. Exp. Ther.* 286, 555–560.
- Ragonese, P., D'Amelio, M., Savettieri, G., 2006. Implications for estrogens in Parkinson's disease: an epidemiological approach. *Ann. N. Y. Acad. Sci.* 1089, 373–382.
- Rebeck, T.R., Troxel, A.B., Wang, Y., Walker, A.H., Panossian, S., Gallagher, S., Shatalova, E.G., Blanchard, R., Bunin, G., DeMichele, A., Rubin, S.C., Baumgarten, M., Berlin, M., Schinnar, R., Berlin, J.A., Strom, B.L., 2006. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. *J. Natl. Cancer Inst.* 98, 1311–1320.
- Reed, M.J., Purohit, A., Woo, L.W., Newman, S.P., Potter, B.V., 2005. Steroid sulfatase: molecular biology, regulation, and inhibition. *Endocr. Rev.* 26, 171–202.
- Saeki, T., Takahashi, S., Sasaki, H., Hanai, N., Salomon, D.S., 1999. Localization of estrone sulfatase in human breast carcinomas. *Breast Cancer* 6, 331–337.
- Santner, S.J., Feil, P.D., Santen, R.J., 1984. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. *J. Clin. Endocrinol. Metab.* 59, 29–33.
- Sato, R., Suzuki, T., Katayose, Y., Miura, K., Shiiba, K., Tateno, H., Miki, Y., Akahira, J., Kamogawa, Y., Nagasaki, S., Yamamoto, K., Ii, T., Egawa, S., Evans, D.B., Unno, M., Sasano, H., 2009. Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of intratumoral estrogen concentrations and potent prognostic factors. *Cancer Res.* 69, 914–922.
- Selcer, K.W., Difrancesca, H.M., Chandra, A.B., Li, P.K., 2007. Immunohistochemical analysis of steroid sulfatase in human tissues. *J. Steroid Biochem. Mol. Biol.* 105, 115–123.
- Shibuya, R., Suzuki, T., Miki, Y., Yoshida, K., Moriya, T., Ono, K., Akahira, J., Ishida, T., Hirakawa, H., Evans, D.B., Sasano, H., 2008. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. *Endocr. Relat. Cancer* 15, 113–124.
- Smuc, T., Rizner, T.L., 2009. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. *Mol. Cell. Endocrinol.* 301, 74–82.
- Stanway, S.J., Purohit, A., Woo, L.W., Sufi, S., Vigushin, D., Ward, R., Wilson, R.H., Stanczyk, F.Z., Dobbs, N., Kulinskaya, E., Elliott, M., Potter, B.V., Reed, M.J., Coombes, R.C., 2006. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. *Clin. Cancer Res.* 12, 1585–1589.
- Suzuki, T., Nakata, T., Miki, Y., Kaneko, C., Moriya, T., Ishida, T., Akinaga, S., Hirakawa, H., Kimura, M., Sasano, H., 2003. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. *Cancer Res.* 63, 2762–2770.
- Suzuki, T., Miki, Y., Nakamura, Y., Moriya, T., Ito, K., Ohuchi, N., Sasano, H., 2005. Sex steroid-producing enzymes in human breast cancer. *Endocr. Relat. Cancer* 12, 701–720.
- Suzuki, M., Ishida, H., Shiotsu, Y., Nakata, T., Akinaga, S., Takahashi, S., Utsumi, T., Saeki, T., Harada, N., 2009. Expression level of enzymes related to in situ estrogen synthesis and clinicopathological parameters in breast cancer patients. *J. Steroid Biochem. Mol. Biol.* 113, 195–201.
- Takase, Y., Luu-The, V., Poisson-Paré, D., Labrie, F., Pelletier, G., 2007. Expression of sulfotransferase 1E1 in human prostate as studied by in situ hybridization and immunocytochemistry. *Prostate* 67, 405–409.
- Tsang, L., Mazella, J., Lee, L.Y., Stone, M.L., 1983. Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. *J. Steroid Biochem.* 4, 1413–1417.
- Tsunoda, Y., Shimizu, Y., Tsunoda, A., Takimoto, M., Sakamoto, M.A., Kusano, M., 2006. Steroid sulfatase in breast carcinoma and change of serum estrogens levels after operation. *Acta Oncol.* 45, 584–589.
- Udler, M.S., Azzato, E.M., Healey, C.S., Ahmed, S., Pooley, K.A., Greenberg, D., Shah, M., Teschendorff, A.E., Caldas, C., Dunning, A.M., Ostrander, E.A., Caporaso, N.E., Easton, D., Pharoah, P.D., 2009. Common germline polymorphisms in COMT, CYP19A1, ESRI, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. *Int. J. Cancer* 125, 2687–2696.
- Utsumi, T., Yoshimura, N., Takeuchi, S., Ando, J., Maruta, M., Maeda, K., Harada, N., 1999. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. *Cancer Res.* 59, 377–381.
- Utsunomiya, H., Ito, K., Suzuki, T., Kitamura, T., Kaneko, C., Nakata, T., Niikura, H., Okamura, K., Yaegashi, N., Sasano, H., 2004. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. *Clin. Cancer Res.* 10, 5850–5856.
- Valle, L.D., Toffolo, V., Nardi, A., Fiore, C., Bernante, P., Di Liddo, R., Parnigotto, P.P., Colombo, L., 2006. Tissue-specific transcriptional initiation and activity of steroid sulfatase complementing dehydroepiandrosterone sulfate uptake and intracrine steroid activations in human adipose tissue. *J. Endocrinol.* 190, 129–139.
- Valle, L.D., Toffolo, V., Nardi, A., Fiore, C., Armanini, D., Belvedere, P., Colombo, L., 2007. The expression of the human steroid sulfatase-encoding gene is driven by alternative first exons. *J. Steroid Biochem. Mol. Biol.* 107, 22–29.
- Wong, N.A., Malcomson, R.D., Jodrell, D.I., Groome, N.P., Harrison, D.J., Saunders, P.T., 2005. ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. *J. Pathol.* 207, 53–60.
- Yamamoto, Y., Yamashita, J., Toi, M., Muta, M., Nagai, S., Hanai, N., Furuya, A., Osawa, Y., Saji, S., Ogawa, M., 2003. Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues. *Oncol. Rep.* 10, 791–796.
- Yoshimura, N., Harada, N., Bukholm, I., Karesen, R., Borresen-Dale, A.L., Kristensen, V.N., 2004. Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. *Breast Cancer Res.* 6, R46–55.
- Zaichuk, T., Ivancic, D., Scholtens, D., Schiller, C., Khan, S.A., 2007. Tissue-specific transcripts of human steroid sulfatase are under control of estrogen signaling pathways in breast carcinoma. *J. Steroid Biochem. Mol. Biol.* 105, 76–84.
- Zhang, H., Varlamova, O., Vargas, F.M., Falany, C.N., Leyh, T.S., 1998. Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase. *J. Biol. Chem.* 273, 10888–10892.



ELSEVIER

Contents lists available at ScienceDirect

# Molecular and Cellular Endocrinology

journal homepage: [www.elsevier.com/locate/mce](http://www.elsevier.com/locate/mce)



## Review

### Inhibition of estrogen actions in human gynecological malignancies: New aspects of endocrine therapy for endometrial cancer and ovarian cancer

Kiyoshi Ito<sup>a,\*</sup>, Hiroki Utsunomiya<sup>a</sup>, Hitoshi Niikura<sup>a</sup>, Nobuo Yaegashi<sup>a</sup>, Hironobu Sasano<sup>b</sup>

<sup>a</sup> Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan

<sup>b</sup> Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan

#### ARTICLE INFO

##### Article history:

Received 15 June 2010  
Received in revised form  
10 November 2010  
Accepted 10 November 2010

##### Keywords:

Estrogen  
Endometrial carcinoma  
Ovarian carcinoma  
Aromatase inhibitor  
Endocrine therapy  
17 $\beta$ -Hydroxysteroid dehydrogenases

#### ABSTRACT

Endometrial carcinoma and possibly ovarian carcinoma are considered “estrogen-dependent tumors” in human gynecological malignancies. In endometrial carcinoma, the enzymes responsible for intratumoral estrogen metabolism and biosynthesis are different from those in human breast carcinoma, although both of them are considered “estrogen-dependent malignancies”. Specific and effective endocrine treatment of endometrial carcinoma should be explored, although progestin agents have been widely used for a long time. Aromatase inhibitors, the most effective endocrine agents of breast carcinoma, retinoids, metabolites of vitamin A, and synthetic peroxisome proliferator-activated receptor (PPAR) gamma ligands, used for the treatment of insulin resistance in type II diabetes mellitus, may be the important candidates for possible endocrine treatment of endometrial carcinoma.

In ovarian carcinoma, several clinical studies recently demonstrated that aromatase inhibitors had some therapeutic activity against recurrent ovarian carcinoma. However, at least at this juncture, further studies should be required to establish an aromatase inhibitor treatment as one form of endocrine therapy of ovarian carcinoma in future.

© 2010 Elsevier Ireland Ltd. All rights reserved.

#### Contents

1. Endometrial carcinoma .....	00
1.1. <i>In situ</i> estrogen production and its regulation .....	00
1.1.1. Intracrinology .....	00
1.1.2. Aromatase .....	00
1.1.3. 17 $\beta$ -Hydroxysteroid dehydrogenase (17-HSD) .....	00
1.1.4. Steroid sulfatase (STS) and estrogen sulfotransferase (EST) .....	00
1.2. Endocrine therapy of endometrial carcinoma .....	00
1.2.1. Progestin therapy .....	00
1.2.2. Aromatase inhibitor .....	00
1.2.3. Retinoids .....	00
1.2.4. Peroxisome proliferator-activated receptor (PPAR) ligand .....	00
2. Ovarian carcinoma .....	00
References .....	00

#### 1. Endometrial carcinoma

##### 1.1. *In situ* estrogen production and its regulation

###### 1.1.1. Intracrinology

Estrogen regulates a wide range of physiological responses in a variety of target tissues. It is well recognized that estrogen plays an important role in the development and progression of endometrial carcinoma. Endometrial carcinoma is one of the most common female pelvic malignancies in developed countries, and its


\* Corresponding author at: Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8557, Japan. Tel.: +81 22 717 7254; fax: +81 22 717 7258.  
E-mail address: [kito@mail.tains.tohoku.ac.jp](mailto:kito@mail.tains.tohoku.ac.jp) (K. Ito).

incidence has recently increased (Jemal et al., 2004). Results of previous clinical, biological and epidemiological studies all demonstrated that excessive and/or prolonged exposure to estrogens not opposed by progesterone is considered to increase the risk of endometrial carcinoma, especially that of the endometrioid type (Thoma, 1984; Kelsey, 1982). However, the great majority of endometrial carcinomas arise during the postmenopausal period when ovaries ceased to be functional. Numerous studies examined the metabolism of serum estrogens in the patients diagnosed with endometrial carcinoma but there have been no consistent evidence of increased serum estrogen concentrations in postmenopausal women with endometrial carcinoma (Potischman et al., 1996; Sherman et al., 1997; Sasano and Harada, 1998; Lukanova et al., 2004).

Recently, a focus has been given to the importance of *in situ* estrogen metabolism, including synthesis and degradation, in the development and progression of various human estrogen-dependent neoplasms, including breast carcinoma. Results of several studies have demonstrated increased tissue estrogen content in human breasts, compared to serum and/or normal non-neoplastic tissues of the same patients (van Landeghem et al., 1985; Pasqualini and Chetrite, 1999; Chetrite et al., 2000). In these studies, the tissue concentrations of estrone (E1), estradiol (E2) and their sulfate metabolites were generally several times higher than those found in the plasma or in the area of the normal breast tissues of the same postmenopausal patients, despite markedly low levels of circulating estrogens. These findings all indicated specific intratumoral biosynthesis and accumulation of these hormones. However, there have been limited and inconsistent data regarding tissue estrogen concentrations in endometrial carcinoma tissues, in contrast to that for breast carcinoma (Bonney et al., 1986; Vermeulen-Meiners et al., 1986; Naitoh et al., 1989; Berstein et al., 2003). Berstein et al. (2003) examined 78 endometrial carcinomas and detected higher concentrations of E2 in cancer tissue specimens compared with macroscopically normal endometrium. Results from our previous studies were generally consistent with those of other investigations (Ito, 2005; Ito et al., 2006). We found that E2, estrone (E1), and testosterone levels in tumor tissues were several times higher than those measured in serum. These findings all indicate that intratumoral estrogen metabolism and synthesis are indeed important in the etiology and progression of endometrial carcinoma. Numerous studies have demonstrated that human endometrial carcinoma tissue contained the enzyme systems required for local biosynthesis of estrogen (Fig. 1). Among these enzymes, aromatase, 17 $\beta$ -hydroxysteroid dehydrogenases (17-HSDs) and steroid sulfatase (STS) are three principal enzymes involved in the formation of biologically active estrogen, estradiol. Estrogen-dependent neoplasms such as breast and endometrioid endometrial carcinoma, in which *in situ* conversions from serum androgens to biologically active estrogens occur, may be considered 'intracrine' tissues. However, the enzymes of 17-HSDs responsible for intratumoral estrogen production are markedly different between human breast and endometrial carcinomas.

### 1.1.2. Aromatase

Aromatase is an enzyme which catalyses the conversion of androgens, mainly androstenedione and testosterone, to E1 and E2, respectively (Bulun et al., 2005). Aromatase is a key enzyme in estrogen synthesis, and the levels of expression in endometrial cancer tissues have been demonstrated to be significantly higher than those in benign endometrial lesions. We previously demonstrated marked aromatase immunoreactivity and mRNA, mainly in the stromal cells or fibroblasts of endometrioid endometrial carcinoma, but not in normal or hyperplastic endometrium (Watanabe et al., 1995). Aromatase expression was significant, both at the protein and mRNA levels, at the site of frank invasion in endometrial




**Fig. 1.** Schema of intratumoral estrogens metabolism and synthesis in endometrial and breast carcinoma. (A) Schema of intratumoral estrogens metabolism and synthesis in breast carcinoma. (B) Schema intratumoral estrogens metabolism and synthesis in endometrial carcinoma. Androgens as substrate are supplied from the circulation. Androstenedione and testosterone are both converted into E1 and E2 by aromatase mainly in stromal cells, respectively. 17 $\beta$ -HSD types 1 and 2 catalyze the reversible conversion of E1 and E2. The local regulation of estrogen activity is quite different between endometrial carcinoma and breast carcinoma. In breast carcinoma, E1 is produced by aromatase and STS. Then, 17 $\beta$ -HSD type 1 converts E1 to E2. 17 $\beta$ -HSD type 1 plays an important role in the regulation of high E2 levels in breast carcinoma tissues. However, 17 $\beta$ -HSD type 1 is not detectable and 17 $\beta$ -HSD type 2 and 5 are essential for the maintenance of E2 concentrations in endometrial carcinoma tissues. Testosterone is produced by 17 $\beta$ -HSD type 5 (conversion mainly from androstenedione to testosterone). In addition, E2 is produced by aromatase (conversion mainly from testosterone to E2). On the other hand, 17 $\beta$ -HSD type 2 expression is decreased through normal endometrium (secretory phase), hyperplasia and finally carcinoma accordingly.

carcinoma, suggesting an induction of aromatase expression by tumor–stromal interactions. In addition, a significant correlation was detected between aromatase expression in stromal cells and poor prognosis in patients with endometrial carcinoma (Segawa et al., 2005). This positive correlation indicates that local aromatase expression plays an important role in tumor progression through the formation of *in situ* estrogens.

It is very important to simulate *in vitro* stromal–carcinoma cell interactions when studying aromatase expression *in vitro*. However, the effects of tumor–stromal interactions on local estrogen biosynthesis in endometrial carcinomas have remained largely unknown. We therefore examined whether estrogen biosynthesis in the tumor microenvironment promotes endometrial carcinoma or not. In order to examine the contribution of stromal cells to estrogen signaling pathways in endometrial carcinoma, we used reporter cells stably transfected with the estrogen response element (ERE) fused to the destabilized green fluorescent protein (GFP) gene (Matsumoto et al., 2008). In this system, the endometrial cancer stromal cells from several patients activated the ERE of carcinoma cells to a variable extent. The GFP expression levels increased when testosterone, a substrate for aromatase, was added to the system. These effects were variably inhibited by aromatase inhibitors, although the response to aromatase inhibitors varied among the patients examined. These results all suggest that GFP expression is driven by estrogen synthesized by aromatase in the endometrial carcinoma stromal cells. In addition, in order to further confirm the local biosynthesis of estrogens and tumor–stromal interactions on aromatase activity, the endometrial carcinoma cell lines





**Fig. 2.** Aromatase activity in IshikawaCO and RL95-2CO with #16 stromal cells was significantly higher than that in IshikawaMO and RL95-2MO. Aromatase assay was done for IshikawaMO, IshikawaCO, RL95-2MO, RL95-2CO, #16MO, and #16CO using 6 $\alpha$ -methylandrosta-4-ene-3,17-dione. The activity was measured by LC–MS/MS method. Mean  $\pm$  SE. +,  $P < 0.01$  versus RL95-2MO; \*,  $P < 0.05$  versus IshikawaMO and versus #16MO. CO; coculture, MO; monoculture, LC–MS/MS; liquid chromatography–tandem mass spectrometry.

Reproduced with permission from Takahashi-Shiga et al. (2009).

(Ishikawa and RL95-2) were co-cultured with stromal cells isolated from endometrial carcinomas, and aromatization activity was measured using liquid chromatography–tandem mass spectrometry (Takahashi-Shiga et al., 2009). We also examined the effects of aromatase inhibitors on cell proliferation. Aromatase activity was significantly higher in co-cultures with Ishikawa and RL95-2 than in each mono-culture, respectively. Cell proliferation was significantly inhibited in Ishikawa and RL95-2 cell cultures treated with aromatase inhibitors compared with control cultures. These *in vitro* findings in co-culture studies did confirm the importance of carcinoma-stromal cells interaction in the process of induction of aromatase in endometrial carcinoma tissues (Fig. 2).

Results of those *in vitro* and *in vivo* studies all demonstrated that aromatase is a key enzyme in the synthesis of estrogen in endometrial carcinoma as well as breast carcinoma.

### 1.1.3. 17 $\beta$ -Hydroxysteroid dehydrogenase (17-HSD)

**1.1.3.1. 17-HSD type 1 and 2.** The 17 $\beta$ -hydroxysteroid dehydrogenases (17-HSDs) catalyzes an interconversion of estrogens or androgens (Luu-The et al., 2001). Among the enzymes, 17-HSD types 1 and 2 catalyze the reversible interconversion of E1 and E2. Type 1 17-HSD catalyzes the 17 $\beta$ -reduction of biologically inactive E1 to E2 (Luu The et al., 1989; Gast et al., 1989), whereas the type 2 isozyme preferentially catalyzes the oxidation of E2 to E1 (Wu et al., 1993). Both type 1 and type 2 17-HSDs regulate tissue levels of E2 and modulate estrogenic actions in estrogen target tissues, such as the breast and endometrium (Sasano et al., 2000). Oxidative 17-HSD activity is the preferential reaction in normal human breast tissues, but the reductive 17-HSD pathway predominates in breast carcinomas. 17-HSD type 1 mRNA levels and intratumoral E2/E1 ratios were significantly higher in postmenopausal compared with premenopausal breast carcinomas (Miyoshi et al., 2001). 17-HSD type 1 immunoreactivity was detected in carcinoma cells in approximately 60% of breast carcinoma tissues, whereas 17-HSD type 2 was not expressed at all (Suzuki et al., 2000). Therefore, type 1 17-HSD is considered responsible for regulating the processes leading to the accumulation of E2 in human breast carcinomas.

In contrast, 17-HSD type 1 immunoreactivity was not detected in any of the cases of normal endometrium, endometrial hyperplasia and endometrioid endometrial carcinoma (Ito et al., 2001;

Utsunomiya et al., 2001). 17-HSD type 1 mRNA expression and enzymatic activity were also absent in all carcinoma cases. In normal endometria, 17-HSD type 2 immunoreactive protein was detected only in the cytoplasm of glandular cells in the secretory phase. 17-HSD type 2 mRNA was also markedly expressed in the endometrial glandular epithelial cells of the luteal phase, but 17-HSD type 1 mRNA was not detected in any of the phases of the examined endometrium (Casey et al., 1994). 17-HSD type 2 immunoreactivity was detected in 75% and 37% of endometrial hyperplasia and endometrioid endometrial carcinoma cases, respectively. 17-HSD type 2 expression was decreased from normal endometrium (secretory phase) to hyperplasia and finally carcinoma (Utsunomiya et al., 2001). In addition, there was a statistically significant inverted correlation between the intratumoral E2 concentration and the level of 17-HSD type 2 mRNA in endometrial carcinoma (Ito et al., 2006). These results all suggest that type 2 17-HSD contributes to the regulation of “intratissue” estrogen levels in normal endometrium and that disruption of the regulatory mechanisms of intratissue estrogen levels may be related to the development and progression of endometrial disorders.

**1.1.3.2. 17-HSD type 5.** 17-HSD type 1 expression is negligible in human endometrioid endometrial carcinoma tissues and intratumoral E2 concentration may be maintained primarily by aromatization of testosterone in endometrial carcinoma. 17-HSD type 5, which catalyzes the reduction of androstenedione to testosterone, is a member of the aldo-keto reductase (AKR) superfamily, and is formally termed AKR1C3 (Dufort et al., 1999). This enzyme is expressed in various peripheral tissues, liver, prostate, and ovary, and has been also detected in prostate and breast carcinoma tissues (Luu-The et al., 2001; Suzuki et al., 2001; Vihko et al., 2004).

17-HSD type 5 immunoreactivity was reported to be present in glandular cells of endometrium, but not in stromal cells (Pelletier et al., 1999; Ito et al., 2006). In normal human endometrium, 17-HSD type 5 immunoreactivity was detected in 19% and 25% of proliferative and secretory phase endometria, respectively. However, 17-HSD type 5 immunoreactivity was detected in 50% and 69% of the cases of endometrial hyperplasia and endometrioid endometrial carcinoma, respectively. 17-HSD type 5 expression was increased significantly throughout normal endometrium, hyperplasia and finally carcinoma (Ito et al., 2006). In addition, there was a statistically significant inverted correlation between intratumoral testosterone concentration and aromatase mRNA level in endometrial carcinoma. Testosterone produced by 17-HSD type 5 in the tumor tissue may be finally aromatized to E2 by aromatase, which is also overexpressed in human endometrial cancer tissues. Although limited information is currently available on 17-HSD type 5 expression in endometrial malignancy, results of our studies did suggest that 17-HSD type 5 is one of the key enzymes in the local regulation of estrogen concentrations in endometrial malignancy.

### 1.1.4. Steroid sulfatase (STS) and estrogen sulfotransferase (EST)

Estrone sulfate (E1S), which is a biologically inactive form of estrogen, exhibits a relatively long half-life in the peripheral blood, and the levels of E1S are 5–10 times higher than those of unconjugated estrogens, such as E1 and E2, during the menstrual cycle and in postmenopausal women (Pasqualini, 2004). STS hydrolyzes circulating E1S to E1, whereas EST (estrogen sulfotransferase) sulfonates E1 to E1S. It was recently suggested that *in situ* estrogen activity in breast carcinoma may be primarily regulated by the status of intratumoral STS and EST (Suzuki et al., 2003). Therefore, the balance between the levels of intratumoral STS and EST may also play an important role in the regulation of *in situ* estrogen levels in estrogen-dependent neoplasms.

In normal endometrium, immunoreactivity to STS was not detected but that to EST was evident during the secretory phase of



the cycle. Both STS and EST immunoreactivity have been detected in 86% and 29% of endometrial carcinoma cases, respectively. Their immunoreactivity was significantly correlated with those of enzymatic activity and mRNA level. In addition, the STS/EST ratio was associated significantly with poor prognosis in endometrial carcinoma patients (Utsunomiya et al., 2004). Similar results were also reported such as that STS/EST ratio of the mRNA level was increased in endometrial carcinoma tissues compared to adjacent normal endometrium (Smuc et al., 2006). Therefore, increased STS and decreased EST expression may contribute to regulation of *in situ* estrogen actions in human endometrial carcinomas, as similar to those in breast carcinomas. Recently, in a hormone-dependent endometrial xenograft model in ovariectomized nude mice, STS inhibitor was reported to be effective in inhibiting endometrial cancer growth (Foster et al., 2008). STS inhibitor may be one of the important candidates as a new endocrine-related agent in endometrial carcinomas as well as breast. However further clarification including pilot clinical studies should be necessary.

## 1.2. Endocrine therapy of endometrial carcinoma

### 1.2.1. Progesterin therapy

The physiological roles of progesterone in the regulation of the glandular epithelium of the endometrium are, in general, considered to antagonize estrogen-mediated cell proliferation and to induce cellular differentiation (Graham and Clarke, 1997). Progestins have been clinically demonstrated to provide some protection against the stimulatory effects of estrogenic agents. For example, hormone replacement therapy using combinations of estrogen and progestin yields a lower risk of endometrial carcinoma, despite an increment in the incidence of breast carcinoma (Beresford et al., 1997; Shumaker et al., 2003).

Accordingly, progestin agents have been extensively used for a long time in patients especially with advanced or recurrent endometrial carcinoma. In the Gynecologic Oncology Group (GOG), women with advanced or recurrent endometrial carcinoma were randomized to either low-dose (200 mg/day) or high-dose (1000 mg/day) medroxyprogesterone acetate (MPA), with response rate of 25% and 15%, respectively (Thigpen et al., 1999). There were no additional benefits to the dose greater than 200 mg/day, and the patients receiving the low-dose displayed a trend towards longer progression-free and overall survivals. This study concluded that oral MPA was active against advanced or recurrent endometrial carcinoma and response to progestin therapy was more frequent among patients with a well-differentiated histology and positive progesterone receptor status.

The standard initial treatment for endometrial carcinoma is obviously staging laparotomy with hysterectomy and bilateral salpingo-oophorectomy, which deprives these patients of any potential for fertility. Therefore, a more conservative medical treatment may be considered in young patients who may happen to wish to preserve their fertility. Approximately 3–5% of patients with these neoplasms are under age of 40, some of whom have been treated with progestin alone as a primary endocrine therapy for both atypical endometrial hyperplasia and early endometrioid endometrial adenocarcinoma. This approach has been supported by several reports in patients desiring to maintain fertility, despite the fact that the subsequent success rate of pregnancy is not necessarily high (Kaku et al., 2001; Shiozawa and Konishi, 2006). Some case reports have revealed that synthesized progestins such as MPA are effective as a conservative treatment of atypical hyperplasia and well differentiated endometrioid endometrial carcinoma. The initial response rate of MPA ranged from 55% to 100% for endometrial carcinoma and 70% to 100% for atypical hyperplasia (Kaku et al., 2001; Shiozawa and Konishi, 2006). In a recent multi-center prospective study, Ushijima et al. (2007) reported the results of 28

cases of endometrioid endometrial carcinoma at presumed stage IA, although it is impossible to verify, and 17 cases of atypical endometrial hyperplasia. Complete response was found in 55% of endometrial carcinoma cases and 82% of atypical hyperplasia cases. During the 3-year follow-up period, 12 pregnancies and seven normal deliveries were achieved after MPA therapy, although 14 recurrences were indeed detected in 30 patients (47%) between 7 and 36 months. Patients should be informed of these greater risks and absolute limitations of this conservative and controversial treatment.

Endometrial carcinoma, especially of the well-differentiated endometrioid type, and atypical hyperplasia often express PR, and their growth is suppressed by progestin. In general, the effect of progestin is considered to be mediated through PR, because the response rate to progestin therapy in PR-positive carcinoma was higher (75%) compared with PR-negative tumors (7%) (Kauppila, 1989). We previously demonstrated that the *in situ* abundance of 17-HSD type 2, which catalyzes the conversion of E2 to E1, and PR, especially PRB, can predict the responsiveness of patients with endometrioid endometrial carcinoma to progestin treatment (Utsunomiya et al., 2003). We also demonstrated that 17-HSD type 2 was only detected in the cytoplasm of the glandular cells during the secretory phase, but not in the proliferative phase endometrium (Utsunomiya et al., 2001). In addition, progestin stimulates the expression of 17-HSD type 2 in epithelial cells of human endometrial tissue (Yang et al., 2001). Progestin may exert a potent anti-estrogenic effect in the endometrium by inducing 17-HSD type 2 and thereby promoting the regression of endometrial proliferative disease.

### 1.2.2. Aromatase inhibitor

Aromatase inhibitors have become the gold standard for endocrine treatments in the postmenopausal patients with estrogen-dependent breast carcinoma (Bulun et al., 2005). Though intratumoral aromatase activity is more frequently detected in endometrial endometrioid carcinoma than in breast carcinoma, there remain several controversies as to whether or not aromatase inhibitors are effective in patients with endometrial carcinoma. (Sasano et al., 1999; Rose et al., 2000; Berstein et al., 2005). We previously examined the biological changes in endometrial carcinoma tissues before and after aromatase inhibitor treatment. Five of 15 human endometrial carcinoma demonstrated decreased [<sup>3</sup>H] thymidine uptake or Ki-67 labeling following aromatase inhibitor treatment (Sasano et al., 1999). Berstein et al. (2005) reported similar results. In our recent study of the local biosynthesis of estrogens and tumor–stromal interactions on aromatase activity, the endometrial carcinoma cell lines were co-cultured with stromal cells isolated from endometrial carcinomas. Cell proliferation was significantly inhibited in endometrial cancer cell cultures treated with aromatase inhibitors compared with control cultures (Takahashi-Shiga et al., 2009). These *in vitro* findings all suggest the effectiveness of aromatase inhibitors in endometrial carcinoma tissues.

However, the therapeutic value of aromatase inhibitor is still not clear at the moment. A GOG study was not able to demonstrate distinct clinical efficacy with aromatase inhibitor treatment. Partial responses were detected in 9% of 23 unselected patients with recurrent or persistent endometrial carcinoma, most of whom had poorly differentiated tumors (Rose et al., 2000). A multi-center phase II trial for letrozol was conducted in 32 recurrent or advanced endometrial carcinomas in postmenopausal women, and only one of 28 (4%) case had a complete response, two (7%) were associated with partial responses, and 11 out of 28 (39%) patients had a stable disease for a median duration of 7 months (Ma et al., 2004). Therefore, the roles of aromatase inhibitors in well-differentiated hormone-receptor-positive or hormone-sensitive endometrial car-

cinoma have remained in dispute. Further studies, including the possibility of application and indication of aromatase inhibitors, are required to establish an aromatase inhibitor treatment as one form of endocrine therapy of endometrial carcinoma in postmenopausal patients. The results of *in vitro* studies may help to achieve improved clinical responses in patients with endometrial carcinoma, who are treated with aromatase inhibitors.

### 1.2.3. Retinoids

Retinoids, metabolites of vitamin A, have been demonstrated to play an important role in *in situ* estrogen metabolism through the regulation of steroid hormone receptors and 17-HSDs. Retinoids are considered to be effective chemopreventive as well as chemotherapeutic agents in a variety of human epithelial and hematopoietic neoplasms, including breast carcinoma (Kudelka et al., 1993; Evans and Kaye, 1999). Kudelka et al. (1993) reported clinically favorable results following retinoid-based treatment of the patients with cisplatin-resistant metastatic endometrial carcinoma. We previously reported that retinoids markedly increased the level of 17-HSD type 2 mRNA in a time- and dose-dependent manner in an endometrial carcinoma cell line (Ito et al., 2001). Retinoid is considered to be involved in the modulation of *in situ* estrogen metabolism by stimulating the expression of 17-HSD type 2. In addition, it has been discovered that expression of retinoic acid receptor (RAR)  $\beta$  is frequently silenced in epithelial carcinogenesis, which has led to the hypothesis that RAR $\beta$  could act as a tumor suppressor. Therefore, we studied the effects of retinoic acid on cell proliferation and the expression of RARs using AM580 (a RAR specific agonist) in the Ishikawa endometrial cancer cell line. *In vitro*, cell growth was inhibited and RAR $\beta$  mRNA was significantly induced by AM580, compared with vehicle controls (Tanabe et al., 2008). Our results suggest that retinoid may be one of the important candidates as a new endocrine-related agent in endometrial carcinoma. However, further studies such as clinical investigations are of course necessary.

### 1.2.4. Peroxisome proliferator-activated receptor (PPAR) ligand

Peroxisome proliferator-activated receptor (PPAR) is a member of the nuclear hormone receptor superfamily of transcription factors. PPAR $\gamma$ , a subfamily of PPARs, plays essential roles in the regulation of lipid homeostasis, adipogenesis, insulin resistance, and in the development of various organs (Ceil and Shuldiner, 2002; Barak et al., 1999). Synthetic PPAR $\gamma$  ligands, known as thiazolidinediones (TZDs), have been used for the treatment of insulin resistance in type II diabetes mellitus. In addition, results of various *in vitro* studies have demonstrated that PPAR $\gamma$  ligands exhibit a potent antiproliferative activity for a wide variety of neoplastic cells (Koeffler, 2003).

The expression and effectiveness of PPAR $\gamma$  have been extensively studied in various human malignancies but little is known about PPAR $\gamma$  in uterine endometrial carcinoma. In addition, the effects of PPAR $\gamma$  agonists on endometrial carcinoma have largely been unknown, although obesity, excess estrogen, type II diabetes, and hypertension are important risk factors for endometrial carcinoma (Berstein et al., 2004; Inoue et al., 2004). Therefore, we examined the expression of PPAR $\gamma$  mRNA and protein in normal endometria and its disorders (Ota et al., 2006). PPAR $\gamma$  immunoreactivity was detected in 11/23 (48%) cases of proliferative phase endometrium, 14/19 (74%) cases of secretory phase endometrium, 27/32 (84%) cases of endometrial hyperplasia, and 67/103 (65%) cases of carcinoma. PPAR $\gamma$  immunoreactivity was significantly lower in endometrial carcinoma than in secretory phase endometrium and in endometrial hyperplasia. In addition, the PPAR $\gamma$  agonist, 15d-PG $_2$  inhibited cell proliferation and induced p21 mRNA in endometrial carcinoma cell lines. These results did suggest that synthetic PPAR $\gamma$  ligands should be important drug can-

didates, not only for prevention but also for endocrine treatment of endometrial carcinoma.

PPARs function as transactivation factors following heterodimerization with retinoid X receptors (RXRs), and bind to specific response elements of various target genes (Mangelsdorf and Evans, 1995). Recently, several studies demonstrated that the combination treatment of PPAR $\gamma$  ligands and RXR ligands (retinoids) enhance the antitumor effects compared to each treatment alone in breast cancer cells (Bonfiglio et al., 2009; Papi et al., 2009). In addition, PPAR $\gamma$  and RXR agonist synergistically suppress proliferation of immortalized endometrial stromal cells (Wu and Guo, 2009). These results all suggest that the combination therapy of PPAR $\gamma$  and RXR ligands may provide a critical strategy for the treatment of endometrial carcinoma in the future.

## 2. Ovarian carcinoma

Ovarian carcinoma is the leading cause of death in the great majority of developed countries. Estrogen has been implicated in the etiology and progression of some ovarian carcinoma. Human ovarian carcinoma occurs in a similar population of peri- and postmenopausal women as those with breast and endometrial carcinoma, and the great majority of human ovarian carcinomas express estrogen receptor (Rao and Slotman, 1991).

Therefore, a focus has been given to the importance of *in situ* estrogen metabolism in the development and progression of ovarian carcinoma as well as breast and endometrial carcinomas. Aromatase is the key enzyme of *in situ* estrogen metabolism and the frequency of aromatase expression ranged from 33% to 81% in ovarian cancer tissues (Watanabe et al., 1995; Cunat et al., 2005; Li et al., 2008). We previously detected marked aromatase immunoreactivity and mRNA, mainly in the stromal cells of ovarian carcinoma (Kaga et al., 1996). Aromatase immunoreactivity was pronounced at sites of frank invasion. On the other hand, aromatase expression has been reported to be also present in epithelial ovarian cancer cells (Cunat et al., 2005). Therefore, ovarian epithelial or carcinoma cells and stromal cells may both produce estrogen through aromatase expression. Those findings provide a basis for ascertaining an effectiveness of aromatase inhibitor in ovarian carcinomas. We previously examined the biological changes in ovarian carcinoma tissues before and after aromatase inhibitor treatment (Sasano et al., 1999). Four of nine human ovarian carcinoma demonstrated decreased [ $^3$ H] thymidine uptake or Ki-67 labeling following aromatase inhibitor treatment. The responsive cases tended to be associated with higher aromatase and ER $\alpha$  than the unresponsive cases did.

In clinical studies, aromatase inhibitor treatment has been demonstrated to elicit clinical response rates up to 35.7% of the patients and stable disease of rates of 20–42% in patients with recurrent ovarian carcinoma (Bowman et al., 2002; Smyth et al., 2007; Li et al., 2008). Since aromatase inhibitor treatment cannot benefit all the patients with recurrent ovarian cancers, it should be important to identify those patients who do have aromatase inhibitor-responsive cancers. In a phase II trial of the aromatase inhibitor (letrozole) in the patients with recurrent ovarian carcinoma, CA125 response was associated with estrogen receptor expression (Bowman et al., 2002; Smyth et al., 2007). In addition, increased expression of aromatase was significantly associated with CA125 response on letrozole treatment (Walker et al., 2007). Those studies did show aromatase inhibitors have some therapeutic activity against recurrent ovarian carcinoma. Further studies should be however, required to establish an aromatase inhibitor treatment as one form of endocrine therapy of human epithelial ovarian carcinoma in postmenopausal patients.

References

- Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., Evans, R.M., 1999. PPAR gamma is required for placental, cardiac, and adipose tissue development. *Mol. Cell* 4, 585–595.
- Beresford, S.A., Weiss, N.S., Voigt, L.F., McKnight, B., 1997. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. *Lancet* 349, 458–461.
- Berstein, L., Kovalevskij, A., Zimarina, T., Maximov, S., Gershfeld, E., Vasilyev, D., Baisheva, S., Baymakhshava, A., Thijssen, J.H., 2005. Aromatase and comparative response to its inhibitors in two types of endometrial cancer. *J. Steroid Biochem. Mol. Biol.* 95, 71–74.
- Berstein, L.M., Kvatchevskaya, J.O., Poroshina, T.E., Kovalenko, I.G., Tsyrlina, E.V., Zimarina, T.S., Ourmantcheeva, A.F., Ashrafiyan, L., Thijssen, J.H., 2004. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer. *J. Cancer Res. Clin. Oncol.* 130, 687–693.
- Berstein, L.M., Tchernobrovkina, A.E., Gamajunova, V.B., Kovalevskij, A.J., Vasilyev, D.A., Chepik, O.F., Turkevitch, E.A., Tsyrlina, E.V., Maximov, S.J., Ashrafiyan, L.A., Thijssen, J.H., 2003. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. *J. Cancer Res. Clin. Oncol.* 129, 245–249.
- Bonney, R.C., Scanlon, M.J., Jones, D.L., Reed, M.J., Anderson, M.C., James, V.H., 1986. The relationship between oestradiol metabolism and adrenal steroids in the endometrium of postmenopausal women with and without endometrial cancer. *Eur. J. Cancer Clin. Oncol.* 22, 953–961.
- Bonfigliolo, D., Cione, E., Qi, H., Pingitore, A., Perri, M., Catalano, S., Vizza, D., Panno, M.L., Genchi, G., Fuqua, S.A., Andò, S., 2009. Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. *Am. J. Pathol.* 175, 1270–1280.
- Bowman, A., Gabra, H., Langdon, S.P., Lessells, A., Stewart, M., Young, A., Smyth, J.F., 2002. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. *Clin. Cancer Res.* 8, 2233–2239.
- Bulun, S.E., Lin, Z., Imir, G., Amin, S., Demura, M., Yilmaz, B., Martin, R., Utsunomiya, H., Thung, S., Gurates, B., Tamura, M., Langoi, D., Deb, S., 2005. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. *Pharmacol. Rev.* 57, 359–383.
- Casey, M.L., MacDonald, P.C., Andersson, S., 1994. 17-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progesterin regulation of gene expression in human endometrium. *J. Clin. Invest.* 94, 2135–2141.
- Ceill, F.S., Shuldiner, A.R., 2002. The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity. *Curr. Diab. Rep.* 2, 179–185.
- Chetrite, G.S., Cortes-Prieto, J., Philippe, J.C., Wright, F., Pasqualini, J.R., 2000. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. *J. Steroid Biochem. Mol. Biol.* 72, 23–27.
- Cunat, S., Rabenoelina, F., Daurès, J.P., Katsaros, D., Sasano, H., Miller, W.R., Maude-londe, T., Pujol, P., 2005. Aromatase expression in ovarian epithelial cancers. *J. Steroid Biochem. Mol. Biol.* 93, 15–24.
- Dufort, I., Rheault, P., Huang, X.F., Soucy, P., Luu-The, V., 1999. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. *Endocrinology* 140, 568–574.
- Evans, T.R., Kaye, S.B., 1999. Retinoids: present role and future potential. *Br. J. Cancer* 80, 1–8.
- Foster, P.A., Woo, L.W., Potter, B.V., Reed, M.J., Purohit, A., 2008. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. *Endocrinology* 149, 4035–4042.
- Gast, M.J., Sims, H.F., Murdock, G.L., Gast, P.M., Strauss, A.W., 1989. Isolation and sequencing of a complementary deoxyribonucleic acid clone encoding human placental 17 beta-estradiol dehydrogenase: identification of the putative cofactor binding site. *Am. J. Obstet. Gynecol.* 161, 1726–1731.
- Graham, J.D., Clarke, C.L., 1997. Physiological action of progesterone in target tissues. *Endocr. Rev.* 18, 502–519.
- Ito, K., Suzuki, T., Moriya, T., Utsunomiya, H., Sugawara, A., Konno, R., Sato, S., Sasano, H., 2001. Retinoid receptors in the human endometrium and its disorders: a possible modulator of 17 beta-hydroxysteroid dehydrogenase. *J. Clin. Endocrinol. Metab.* 86, 2721–2727.
- Ito, K., 2005. In situ estrogen metabolism and synthesis in endometrium and breast. *Acta Obstet. Gynaec. Jpn.* 57, 1819–1827.
- Ito, K., Utsunomiya, H., Suzuki, T., Saitou, S., Akahira, J., Okamura, K., Yaegashi, N., Sasano, H., 2006. 17Beta-hydroxysteroid dehydrogenases in human endometrium and its disorders. *Mol. Cell. Endocrinol.* 248, 136–140.
- Inoue, M., Sobue, T., Tsugane, S., for the JPHC Study Group, 2004. Impact of body mass index on the risk of total cancer incidence and mortality among middle-aged Japanese: data from a large-scale population-based cohort study – The JPHC Study. *Cancer Causes Control* 15, 671–680.
- Jemal, A., Tiwari, R.C., Murray, T., Samuels, A., Ward, E., Feuer, E.J., Thun, M.J., American Cancer Society, 2004. Cancer statistics 2004. *CA Cancer J. Clin.* 54, 8–29.
- Kaga, K., Sasano, H., Harada, N., Ozaki, M., Sato, S., Yajima, A., 1996. Aromatase in human common epithelial ovarian neoplasms. *Am. J. Pathol.* 149, 45–51.
- Kaku, T., Yoshikawa, H., Tsuda, H., Sakamoto, A., Fukunaga, M., Kuwabara, Y., Hataeg, M., Kodama, S., Kuzuya, K., Sato, S., Nishimura, T., Hiura, M., Nakano, H., Iwasaki, T., Miyazaki, K., Kamura, T., 2001. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. *Cancer Lett.* 167, 39–48.
- Kaupilla, A., 1989. Oestrogen and progesterin receptors as prognostic indicators in endometrial cancer. A review of the literature. *Acta Oncol.* 28, 561–566.
- Kelsey, J.L., 1982. A case control study of cancer of the endometrium. *Am. J. Epidemiol.* 116, 333–342.
- Koeffler, H.P., 2003. Peroxisome proliferators-activated receptor gamma and carcinomas. *Clin. Cancer Res.* 9, 1–9.
- Kudelka, A.P., Freedman, R.S., Edwards, C.L., Lippman, S.M., Tornos, C.S., Krakoff, I.H., Kavanagh, J.J., 1993. Metastatic adenocarcinoma of the endometrium treated with 13-cis-retinoic acid plus interferon-alpha. *Anticancer Drugs* 4, 335–337.
- Li, Y.F., Hu, W., Fu, S.Q., Li, J.D., Liu, J.H., Kavanagh, J.J., 2008. Aromatase inhibitors in ovarian cancer: is there a role? *Int. J. Gynecol. Cancer* 18, 600–614.
- Luu-The, V., Dufort, I., Pelletier, G., Labrie, F., 2001. Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. *Mol. Cell. Endocrinol.* 171, 77–82.
- Luu The, V., Labrie, C., Zhao, H.F., Couet, J., Lachance, Y., Simard, J., Leblanc, G., Cote, J., Berube, D., Gagne, R., 1989. Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta. *Mol. Endocrinol.* 3, 1301–1309.
- Lukanova, A., Lundin, E., Micheli, A., Arslan, A., Ferrari, P., Rinaldi, S., Krogh, V., Lenner, P., Shore, R.E., Biessy, C., Muti, P., Riboli, E., Koenig, K.L., Levitz, M., Stattin, P., Berrino, F., Hallmans, G., Kaaks, R., Toniolo, P., Zeleniuch-Jacquotte, A., 2004. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. *Int. J. Cancer* 108, 425–432.
- Ma, B.B., Oza, A., Eisenhauer, E., Stanimir, G., Carey, M., Chapman, W., Latta, E., Sidhu, K., Powers, J., Walsh, W., Fyles, A., 2004. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group. *Int. J. Gynecol. Cancer* 14, 650–658.
- Mangelsdorf, D.J., Evans, R.M., 1995. The RXR heterodimers and orphan receptors. *Cell* 83, 841–850.
- Matsumoto, M., Yamaguchi, Y., Seino, Y., Hatakeyama, A., Takei, H., Niikura, H., Ito, K., Suzuki, T., Sasano, H., Yaegashi, N., Hayashi, S., 2008. Estrogen signaling ability in human endometrial cancer through the cancer–stromal interaction. *Endocr. Relat. Cancer* 15, 451–463.
- Miyoshi, Y., Ando, A., Shiba, E., Taguchi, T., Tamaki, Y., Noguchi, S., 2001. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. *Int. J. Cancer* 94, 685–689.
- Naitoh, K., Honjo, H., Yamamoto, T., Urabe, M., Ogino, Y., Yasumura, T., Nambara, T., 1989. Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer. *J. Steroid Biochem.* 33, 1049–1054.
- Ota, K., Ito, K., Suzuki, T., Saito, S., Tamura, M., Hayashi, S., Okamura, K., Sasano, H., Yaegashi, N., 2006. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. *Clin. Cancer Res.* 12, 4200–4208.
- Papi, A., Rocchi, P., Ferreri, A.M., Guerra, F., Orlandi, M., 2009. Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells. *Oncol. Rep.* 21, 1083–1089.
- Pasqualini, J.R., Chetrite, G.S., 1999. Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. *J. Steroid Biochem. Mol. Biol.* 69, 287–292.
- Pasqualini, J.R., 2004. The selective estrogen enzyme modulators in breast cancer: a review. *Biochim. Biophys. Acta* 1654, 123–143.
- Pelletier, G., Luu-The, V., Tetu, B., Labrie, F., 1999. Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. *J. Histochem. Cytochem.* 47, 731–738.
- Potischman, N., Hoover, R.N., Brinton, L.A., Siiteri, P., Dorgan, J.F., Swanson, C.A., Berman, M.L., Mortel, R., Twigg, L.B., Barrett, R.J., Wilbanks, G.D., Persky, V., Lurain, J.R., 1996. Case-control study of endogenous steroid hormones and endometrial cancer. *J. Natl. Cancer Inst.* 88, 1127–1135.
- Rao, B.R., Slotman, B.J., 1991. Endocrine factors in common epithelial ovarian cancer. *Endocr. Rev.* 12, 14–26.
- Rose, P.G., Brunetto, V.L., VanLe, L., Bell, J., Walker, J.L., Lee, R.B., 2000. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. *Gynecol. Oncol.* 78, 212–216.
- Sasano, H., Harada, N., 1998. Intratumoral aromatase in human breast, endometrial and ovarian malignancy. *Endocr. Soc.* 19, 593–607.
- Sasano, H., Suzuki, T., Takeyama, J., Utsunomiya, H., Ito, K., Ariga, N., Moriya, T., 2000. 17-beta-hydroxysteroid dehydrogenase in human breast and endometrial carcinoma. A new development in intracrinology. *Oncology* 59, 5–12.
- Sasano, H., Sato, S., Ito, K., Yajima, A., Nakamura, J., Yoshihama, M., Ariga, K., Anderson, T.J., Miller, W.R., 1999. Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. *Endocr. Relat. Cancer* 6, 197–204.
- Segawa, T., Shozu, M., Murakami, K., Kasai, T., Shinohara, K., Nomura, K., Ohno, S., Inoue, M., 2005. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. *Clin. Cancer Res.* 11, 2188–2194.
- Sherman, M.E., Sturgeon, S., Brinton, L.A., Potischman, N., Kurman, R.J., Berman, M.L., Mortel, R., Twigg, L.B., Barrett, R.J., Wilbanks, G.D., 1997. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. *Mod. Pathol.* 10, 963–968.
- Shiozawa, T., Konishi, I., 2006. Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. *Int. J. Clin. Oncol.* 11, 13–21.

- Shumaker, S.A., Legault, C., Rapp, S.R., Thal, L., Wallace, R.B., Ockene, J.K., Hendrix, S.L., Jones 3rd, B.N., Assaf, A.R., Jackson, R.D., Kotchen, J.M., Wassertheil-Smoller, S., Wactawski-Wende, J., WHIMS Investigators, 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA* 289, 2651–2662.
- Smuc, T., Ruprecht, R., Sinkovec, J., Adamski, J., Rizner, T.L., 2006. Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. *Mol. Cell. Endocrinol.* 248, 114–117.
- Smyth, J.F., Gourley, C., Walker, G., MacKean, M.J., Stevenson, A., Williams, A.R., Nafussi, A.A., Rye, T., Rye, R., Stewart, M., McCurdy, J., Mano, M., Reed, N., McMahon, T., Vasey, P., Gabra, H., Langdon, S.P., 2007. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. *Clin. Cancer Res.* 13, 3617–3622.
- Suzuki, T., Moriya, T., Ariga, N., Kaneko, C., Kanazawa, M., Sasano, H., 2000. 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. *Br. J. Cancer* 82, 518–523.
- Suzuki, T., Darnel, A.D., Akahira, J.I., Ariga, N., Ogawa, S., Kaneko, C., Takeyama, J., Moriya, T., Sasano, H., 2001. 5Alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. *J. Clin. Endocrinol. Metab.* 86, 2250–2257.
- Suzuki, T., Nakata, T., Miki, Y., Kaneko, C., Moriya, T., Ishida, T., Akinaga, S., Hirakawa, H., Kimura, M., Sasano, H., 2003. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. *Cancer Res.* 63, 2762–2770.
- Takahashi-Shiga, N., Utsunomiya, H., Miki, Y., Nagase, S., Kobayashi, R., Matsumoto, M., Niikura, H., Ito, K., Yaegashi, N., 2009. Local biosynthesis of estrogen in human endometrial carcinoma through tumor–stromal cell interactions. *Clin. Cancer Res.* 15, 6028–6034.
- Tanabe, K., Utsunomiya, H., Tamura, M., Niikura, H., Takano, T., Yoshinaga, K., Nagase, S., Suzuki, T., Ito, K., Matsumoto, M., Hayashi, S., Yaegashi, N., 2008. Expression of retinoic acid receptors in human endometrial carcinoma. *Cancer Sci.* 99, 267–271.
- Thigpen, J.T., Brady, M.F., Alvarez, R.D., Adelson, M.D., Homesley, H.D., Manetta, A., Soper, J.T., Given, F.T., 1999. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose–response study by the Gynecologic Oncology Group. *J. Clin. Oncol.* 17, 1736–1744.
- Thoma, D.B., 1984. Do hormones cause cancer? *Cancer* 53, 595–604.
- Ushijima, K., Yahata, H., Yoshikawa, H., Konishi, I., Yasugi, T., Saito, T., Nakanishi, T., Sasaki, H., Saji, F., Iwasaka, T., Hatae, M., Kodama, S., Saito, T., Terakawa, N., Yaegashi, N., Hiura, M., Sakamoto, A., Tsuda, H., Fukunaga, M., Kamura, T., 2007. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J. Clin. Oncol.* 25, 2798–2803.
- Utsunomiya, H., Suzuki, T., Kaneko, C., Takeyama, J., Nakamura, J., Kimura, K., Yoshinaga, M., Harada, N., Ito, K., Konno, R., Sato, S., Okamura, K., Sasano, H., 2001. The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. *J. Clin. Endocrinol. Metab.* 86, 3436–3443.
- Utsunomiya, H., Ito, K., Suzuki, T., Kitamura, T., Kaneko, C., Nakata, T., Niikura, H., Okamura, K., Yaegashi, N., Sasano, H., 2004. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. *Clin. Cancer Res.* 10, 5850–5856.
- Utsunomiya, H., Suzuki, T., Ito, K., Moriya, T., Konno, R., Sato, S., Yaegashi, N., Okamura, K., Sasano, H., 2003. The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. *Clin. Endocrinol.* 58, 696–703.
- van Landeghem, A.A., Poortman, J., Nabuurs, M., Thijssen, J.H., 1985. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. *Cancer Res.* 45, 2900–2906.
- Vermeulen-Meiners, C., Poortman, J., Haspels, A.A., Thijssen, J.H., 1986. The endogenous concentration of estradiol and estrone in pathological human postmenopausal endometrium. *J. Steroid Biochem.* 24, 1073–1078.
- Vihko, P., Harkonen, P., Soronen, P., Torn, S., Herrala, A., Kurkela, R., Pulkka, A., Odunwole, O., Isomaa, V., 2004. 17 Beta-hydroxysteroid dehydrogenases – their role in pathophysiology. *Mol. Cell. Endocrinol.* 215, 83–88.
- Walker, G., MacLeod, K., Williams, A.R., Cameron, D.A., Smyth, J.F., Langdon, S.P., 2007. Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. *Gynecol. Oncol.* 106, 461–468.
- Watanabe, K., Sasano, H., Harada, N., Ozaki, M., Niikura, H., Sato, S., Yajima, A., 1995. Aromatase in human endometrial carcinoma and hyperplasia immunohistochemical, in situ hybridization, and biochemical studies. *Am. J. Pathol.* 146, 491–500.
- Wu, L., Einstein, M., Geissler, W.M., Chan, H.K., Elliston, K.O., Andersson, S., 1993. Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. *J. Biol. Chem.* 268, 12964–12969.
- Wu, Y., Guo, S.W., 2009. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. *Fertil. Steril.* 91, 2142–2147.
- Yang, S., Fang, Z., Gurates, B., Tamura, M., Miller, J., Ferrer, K., Bulun, S.E., 2001. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. *Mol. Endocrinol.* 15, 2093–2105.



Contents lists available at ScienceDirect

The Breast

journal homepage: [www.elsevier.com/brst](http://www.elsevier.com/brst)

Original article

## Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer

Masahiro Takada<sup>a</sup>, Shigehira Saji<sup>b,c,d,\*</sup>, Norikazu Masuda<sup>e</sup>, Katsumasa Kuroi<sup>d</sup>, Nobuaki Sato<sup>f</sup>, Hiroyuki Takei<sup>g</sup>, Yutaka Yamamoto<sup>h</sup>, Shinji Ohno<sup>i</sup>, Hiroko Yamashita<sup>j</sup>, Kazufumi Hisamatsu<sup>k</sup>, Kenjiro Aogi<sup>l</sup>, Hiroji Iwata<sup>m</sup>, Takayuki Ueno<sup>a</sup>, Hironobu Sasano<sup>n</sup>, Masakazu Toi<sup>a</sup>

<sup>a</sup> Department of Surgery (Breast Surgery), Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan

<sup>b</sup> Department of Target Therapy Oncology, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan

<sup>c</sup> Department of Medical Oncology, Saitama Medical University, International Medical Center, Saitama 350-1298, Japan

<sup>d</sup> Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo 113-8677, Japan

<sup>e</sup> Department of Surgery and Breast Oncology, Osaka National Hospital, Osaka 540-0006, Japan

<sup>f</sup> Department of Surgery, Niigata Cancer Center Hospital, Niigata 951-8566, Japan

<sup>g</sup> Division of Breast Surgery, Saitama Cancer Center, Saitama 362-0806, Japan

<sup>h</sup> Department of Breast & Endocrine Surgery, Kumamoto University, Kumamoto 860-8556, Japan

<sup>i</sup> Department of Breast Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan

<sup>j</sup> Department of Breast & Endocrine Surgery, Nagoya City University Hospital, Aichi 467-8602, Japan

<sup>k</sup> Department of Surgery, Hiroshima City Asa Hospital, Hiroshima 731-0293, Japan

<sup>l</sup> Department of Breast Oncology, National Shikoku Cancer Center, Ehime 791-0280, Japan

<sup>m</sup> Department of Breast Oncology, Aichi Cancer Center Hospital, Aichi 464-8681, Japan

<sup>n</sup> Department of Pathology, Tohoku University Hospital and School of Medicine, Miyagi 980-8574, Japan

### ARTICLE INFO

#### Article history:

Received 11 May 2011

Received in revised form

17 July 2011

Accepted 20 July 2011

#### Keywords:

Body mass index

Predictive factor

Neoadjuvant hormonal therapy

Aromatase inhibitor

Exemestane

Breast cancer

### ABSTRACT

**Background:** Some studies have shown that high body mass index (BMI) is associated with inferior outcome after adjuvant therapy with anastrozole in breast cancer patients. We aimed to investigate predictive effect of BMI on clinical response to neoadjuvant therapy with exemestane in postmenopausal patients with primary breast cancer.

**Patients and methods:** The study group consisted of 109 patients from the JFMC 34-0601 neoadjuvant endocrine therapy trial. Patients were categorized into three groups according to BMI: low (BMI < 22 kg/m<sup>2</sup>), intermediate (22 ≤ BMI < 25 kg/m<sup>2</sup>) and high (BMI ≥ 25 kg/m<sup>2</sup>). Statistical analyses were performed to explore the predictive effect of BMI on clinical response.

**Results:** Higher BMI correlated with positive progesterone receptor status ( $p < 0.01$ ) and low Ki-67 index ( $p = 0.03$ ). Objective response rates (ORR) were 21.7% in low BMI, 56.0% in intermediate BMI and 60.6% in high BMI, respectively ( $p = 0.01$ ). In a multivariate analysis, low BMI was an independent negative predictor of clinical response.

**Conclusion:** Low BMI was associated with a decreased ORR to neoadjuvant endocrine therapy with exemestane. Our results may suggest that the predictive effect of BMI varies according to the type of aromatase inhibitor and objective outcome.

© 2011 Elsevier Ltd. All rights reserved.

### Introduction

Aromatase inhibitors have been widely used in postmenopausal patients with hormone receptor-positive breast cancer. Patients

treated with third-generation aromatase inhibitors showed lower recurrence rates compared to those treated with tamoxifen in an adjuvant setting.<sup>1–3</sup>

Obesity, which is measured using body mass index (BMI), is a prognostic indicator in patients with primary breast cancer.<sup>4–6</sup> It is assumed that obesity affects the circulating plasma levels of estrogen, insulin, insulin-like growth factor or other hormonal factors, which may lead to tumor growth.<sup>7</sup> In postmenopausal women, the conversion of androgens to estrogens

\* Corresponding author. Present address: Department of Target Therapy Oncology, Kyoto University, Graduate School of Medicine, Kyoto 606-8507, Japan. Tel.: +81 75 751 3660; fax: +81 75 751 3616.

E-mail address: [ss-saji@wa2.so-net.ne.jp](mailto:ss-saji@wa2.so-net.ne.jp) (S. Saji).



in adipose tissue is regarded as a major source of estrogen supply.

The prognostic effect of BMI has also been shown in patients treated with hormonal therapy.<sup>8–10</sup> Several studies have suggested that the efficacy of hormonal therapy on overall and disease-free survival varies according to BMI. In the ATAC trial, anastrozole, a non-steroidal aromatase inhibitor, was significantly less effective in postmenopausal breast cancer patients with high BMI, whereas an equal efficacy of tamoxifen was shown across all BMI levels.<sup>10</sup> However, the relationship between BMI and clinical treatment response to hormonal therapy has not been described. Therefore, we investigated whether BMI is also predictive of treatment response to exemestane, a steroidal aromatase inhibitor, in postmenopausal patients with primary breast cancer who participated in the clinical trial of neoadjuvant hormonal therapy (Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor-positive Stage II or IIIA breast cancer (JFMC34-0601, UMIN Clinical Trial ID; C000000345)).<sup>11</sup>

## Patients and methods

### Patients and treatment

Postmenopausal women aged 55–75 years with operable, Stage II or IIIA estrogen receptor (ER)-positive primary breast cancers were prospectively included in this clinical trial JFMC 34-0601. Details of the study design, methods, primary objectives and major outcomes have been described previously.<sup>11</sup> This study was performed in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Research of the Ministry of Health, Labour and Welfare of Japan. Approval was obtained from the institutional review board at each study centre. Written informed consent was obtained from all patients before enrollment.

Patients were initially treated with 25 mg exemestane once daily, orally, for 16 weeks and then clinical response was assessed. Patients with progressive disease were withdrawn from the study and the remainder continued the treatment for additional 8 weeks. After 24 weeks of treatment, clinical response was evaluated again and surgery was performed.

### Evaluation

Clinical response was evaluated using ultrasonography. We employed two kinds of response evaluation criteria. One was the Response Evaluation Criteria in Solid Tumors (RECIST), wherein target lesions are measured by uni-dimensional measurements (the maximum axial diameter) and the other was the World Health Organization (WHO) criteria wherein target lesions are measured by bi-dimensional measurements (cross-sectional longest diameters).<sup>12,13</sup> Tumor reduction rate from the baseline measurement was subsequently calculated and response was evaluated based on each criteria.

Pathological response was categorized using the modified criteria described previously by Miller et al.<sup>14</sup> and assessed as follows: a complete response, when there was no evidence of malignant cells at the original tumor site; partial response, when histological decrease in cellularity and/or an increase in fibrosis was detected; and non-response, where there was no change.

The status of the ER, progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2) and Ki-67 were evaluated by immunohistochemical (IHC) analyses, as described before.<sup>11</sup> Patients were defined as positive for ER or PgR when 10% or more nuclear staining was observed. Positive HER2 status was defined as either 3+ or 2+ by IHC with confirmed c-erbB2 gene amplification by the fluorescent *in situ* hybridization test. In this study, the

median baseline value of the Ki-67 index was 11%. Therefore, Ki-67 was categorized as positive if the index was 11% or more.

BMI was defined as weight in kilograms divided by the square of the height in meters (kg/m<sup>2</sup>).

### Statistical methods

First, we evaluated the relationship between baseline clinicopathological characteristics and BMI using the chi-square or Kruskal–Wallis test. Second, we analyzed the correlation between pathological response and tumor reduction rate measured by uni- and bi-dimensional criteria using the Wilcoxon rank-sum test. Finally, we performed univariate and multivariate analyses to evaluate the predictive effect of BMI on clinical response. Clinical response was divided into two categories based on the tumor reduction rate. Objective response for the WHO criteria was defined as patients whose tumors showed 50% or more reduction by the bi-dimensional measurements. Objective response in the RECIST criteria was defined as a 30% or more reduction in the uni-dimensional measurements. The chi-square test was used for the univariate analysis. Multivariate analysis was performed using a multivariate logistic regression model. Variables included in the multivariate analysis were BMI, age, clinical nodal status, PgR status and the Ki-67 index. Tumor size and HER2 status were excluded from the analysis because most patients were clinical T2-stage and HER2 negative (Table 1). Patients with missing values were excluded from the analysis. Analyses were performed using JMP® for Windows (release 8.0.2.2: SAS Institute Inc, Cary, NC, USA).

## Results

### BMI and patient characteristics

A total of 116 patients were enrolled in this study. Of these, 109 patients, whose baseline BMI was available were included in this analysis. Fig. 1 shows the distribution of patients according to BMI. The BMI ranged from 17.4 to 38.8 kg/m<sup>2</sup> (median, 23.7 kg/m<sup>2</sup>). BMI was categorized as low (BMI < 22 kg/m<sup>2</sup>), intermediate (22 ≤ BMI < 25 kg/m<sup>2</sup>) and high (BMI ≥ 25 kg/m<sup>2</sup>). We employed cut-off points, as they have some clinical meaning (WHO cut-off points or standard body mass in Japan) and thus we could divide the patients into three groups of approximately the same size.

Table 1 shows the baseline patient and tumor characteristics according to the BMI groups ( $n = 109$ ). All patients were ER positive and most patients were clinical T2-stage and HER2 negative. The BMI groups correlated significantly with PgR status and Ki-67 index ( $p < 0.01$  and  $p = 0.03$ , respectively).

### Clinical response, pathological response and BMI

Next, we analyzed the correlation between pathological response and tumor reduction rate measured by uni- and bi-dimensional criteria. All of the pathological responders had a partial response, whereas the remainder were non-responders. Information about pathological response and/or clinical response at 24 weeks was not available in 29 patients. Therefore, 24 pathological responders and 56 non-responders were included in the analysis. Pathological responders showed a significantly higher reduction rate based on the bi-dimensional measurements ( $p = 0.04$ ). In contrast, no significant difference in reduction rate was observed based on the uni-dimensional measurements and pathological response (Fig. 2).

Fig. 3 shows the objective response rate (ORR) based on the WHO criteria at 24 weeks according to the BMI groups. The ORR in the low BMI group decreased significantly compared with that of